data_2mof_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mof _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 120.587 0.232 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.165 0 CA-C-O 120.732 0.301 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 390' ' ' ILE . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 398' ' ' ILE . 95.7 mt . . . . . 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.276 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.473 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.473 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 398' ' ' ILE . 96.2 mt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.331 0 CA-C-O 120.607 0.242 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.412 HD12 HG21 ' A' ' 390' ' ' ILE . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.334 0 CA-C-O 120.767 0.318 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.283 0 CA-C-O 120.475 0.178 . . . . 0.0 110.704 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 CA-C-O 120.586 0.231 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 398' ' ' ILE . 97.3 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.509 0.195 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.455 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.401 HG21 HD11 ' A' ' 390' ' ' ILE . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.408 HD11 HG21 ' A' ' 398' ' ' ILE . 97.6 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.743 0.306 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.263 0 CA-C-O 120.543 0.211 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 398' ' ' ILE . 97.4 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.55 0.214 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.478 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.4 HG22 HD11 ' A' ' 390' ' ' ILE . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.742 0.306 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.41 HD12 HG23 ' A' ' 398' ' ' ILE . 97.8 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.2 0 CA-C-O 120.796 0.331 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.402 HD12 HG21 ' A' ' 390' ' ' ILE . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.273 0 CA-C-O 120.636 0.255 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.477 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.346 0 CA-C-O 120.594 0.235 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.443 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.443 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 390' ' ' ILE . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.272 0 CA-C-O 120.594 0.235 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.401 HD13 HG22 ' A' ' 390' ' ' ILE . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.817 0.342 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.692 0.282 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 381' ' ' VAL . . . . . 0.474 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 382' ' ' GLY . . . . . 0.474 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 390' ' ' ILE . . . . . 0.44 HD11 HG21 ' A' ' 390' ' ' ILE . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 398' ' ' ILE . . . . . 0.408 HG21 HD12 ' A' ' 398' ' ' ILE . 91.7 mt . . . . . 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.37 139.74 49.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.51 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -153.52 173.79 15.26 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.855 0.359 . . . . 0.0 110.324 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -90.05 110.44 21.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.505 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -87.47 0.49 55.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.416 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -64.01 -41.09 97.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.55 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -63.64 -41.86 98.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.439 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 10.1 mp -81.07 137.85 35.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.389 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 18.5 t 44.06 73.33 0.98 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.528 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.13 144.21 99.47 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.897 2.398 . . . . 0.0 112.151 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.6 mt -64.42 -43.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.835 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.18 -41.36 89.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.78 -37.84 94.96 Favored Glycine 0 CA--C 1.519 0.314 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' A' ' 401' ' ' LYS . 41.6 tp -62.53 -42.5 99.56 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.8 tttt 59.2 140.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.694 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 65.9 t-80 -70.6 137.74 50.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.451 ' CD2' ' O ' ' A' ' 404' ' ' HIS . 82.0 t60 -75.25 134.49 41.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.506 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . 0.451 ' O ' ' CD2' ' A' ' 403' ' ' HIS . 76.3 m80 -68.56 140.17 55.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.479 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.74 -11.31 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.662 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -35.16 91.72 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.2 t80 -82.87 130.07 35.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.742 0.306 . . . . 0.0 110.49 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -85.22 115.93 23.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.454 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 50.1 tp60 -73.31 132.61 43.29 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.561 179.617 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.64 146.97 26.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.06 0.457 . . . . 0.0 110.515 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -61.58 -42.34 98.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.374 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 46.7 t0 56.3 40.18 29.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.425 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -68.15 144.47 54.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.506 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -86.53 109.7 19.28 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.573 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.412 ' CD1' ' O ' ' A' ' 376' ' ' LEU . 23.1 t80 -149.86 120.38 7.44 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.239 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.53 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 8.2 mp -77.92 148.5 34.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.111 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' A' ' 376' ' ' LEU . 4.0 m 31.37 74.48 0.45 Allowed Pre-proline 0 N--CA 1.468 0.462 0 O-C-N 123.738 0.649 . . . . 0.0 111.009 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.35 145.57 98.36 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 122.917 2.412 . . . . 0.0 112.12 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.9 -42.97 97.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.256 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.05 -19.93 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.413 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.52 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.405 HD13 HG22 ' A' ' 390' ' ' ILE . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.403 HD13 HG21 ' A' ' 398' ' ' ILE . 95.7 mt -63.71 -42.61 96.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -40.4 97.67 Favored Glycine 0 CA--C 1.521 0.419 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 45.8 tp -62.79 -41.9 99.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -74.28 139.1 44.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.45 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -150.2 144.1 25.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -81.03 128.66 33.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.273 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -99.28 137.82 37.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.458 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -13.34 59.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.583 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.82 -38.75 96.6 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.15 139.01 50.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.761 0.315 . . . . 0.0 110.537 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.89 118.74 23.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.22 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -52.79 138.69 28.7 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.543 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 86.2 t80 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.489 179.753 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.77 146.49 51.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.619 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.54 -45.18 95.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.157 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 68.1 t0 -67.92 133.67 49.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.477 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.52 ' CG ' ' H ' ' A' ' 374' ' ' ASN . 41.6 t0 56.36 -173.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.468 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.52 ' H ' ' CG ' ' A' ' 373' ' ' ASP . 98.8 m-20 55.05 39.46 31.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.473 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -81.74 83.26 7.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.691 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 10.9 mp -91.92 131.27 37.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.959 0.409 . . . . 0.0 110.332 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.441 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.6 t 56.52 54.28 7.93 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.441 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 40.0 Cg_endo -66.76 152.48 80.47 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.824 2.35 . . . . 0.0 112.024 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.0 mt -64.94 -43.25 96.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.52 -19.67 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.276 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.473 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.413 HD13 HG22 ' A' ' 398' ' ' ILE . 96.2 mt -64.62 -42.55 95.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.91 -40.07 98.82 Favored Glycine 0 C--N 1.333 0.392 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 48.5 tp -62.73 -41.36 99.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.425 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -61.45 -41.27 96.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.593 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -151.37 136.21 17.25 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.415 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 83.4 t60 -74.14 129.2 37.37 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.443 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 50.6 t60 -76.61 127.88 33.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.3 -11.78 59.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.693 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.58 -35.84 92.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -83.11 132.99 35.08 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.733 0.302 . . . . 0.0 110.538 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -84.46 116.37 23.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.532 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.602 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.88 146.26 11.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.565 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.472 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 86.7 t80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.963 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.54 151.12 31.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.438 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -144.32 106.86 4.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.858 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 55.9 36.73 27.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.18 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 376' ' ' LEU . 47.9 t0 -63.66 -39.34 94.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.075 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.1 -39.55 94.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.754 0.312 . . . . 0.0 110.983 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -59.26 -44.72 92.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.755 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.449 ' O ' ' O ' ' A' ' 373' ' ' ASP . 10.6 mt -99.57 130.95 45.86 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.457 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.2 t 60.04 58.87 4.44 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.19 163.56 38.34 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.748 2.299 . . . . 0.0 112.057 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -62.36 -42.44 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.13 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.89 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.809 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.412 HD12 HG21 ' A' ' 390' ' ' ILE . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.91 -42.49 94.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 403' ' ' HIS . . . -62.1 -33.29 85.3 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.2 tp -61.59 -42.39 98.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.339 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.528 ' C ' ' H ' ' A' ' 403' ' ' HIS . 99.4 mttt -98.21 151.74 20.13 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.362 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 28.5 t60 69.96 -38.65 0.41 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.708 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.528 ' H ' ' C ' ' A' ' 401' ' ' LYS . 98.5 m-70 -115.17 145.04 42.78 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -100.4 131.87 46.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.391 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -12.79 59.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.609 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.38 -40.26 97.65 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -88.52 128.18 35.55 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.738 0.304 . . . . 0.0 110.509 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -135.18 146.07 48.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.425 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.509 ' CD ' ' N ' ' A' ' 409' ' ' GLN . 3.1 pm0 -130.46 146.7 52.06 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.509 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.502 ' CD1' ' OXT' ' A' ' 410' ' ' PHE . 54.5 p90 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.592 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 92.9 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -162.86 155.8 19.36 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.669 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -61.79 -41.96 98.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.418 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -86.31 111.68 20.69 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.467 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 67.5 t0 -66.41 136.06 55.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.487 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.483 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 46.7 p30 -155.29 167.11 31.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.227 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 45.6 t80 -145.69 121.81 10.78 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.203 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.447 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.9 mp -72.65 139.62 47.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.094 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 t 61.69 56.71 3.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.608 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.74 160.46 48.14 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.686 2.257 . . . . 0.0 112.031 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.5 mm -64.98 -42.06 93.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.323 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.91 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.448 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 379' ' ' ILE . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.42 -41.44 83.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.23 -32.26 83.52 Favored Glycine 0 N--CA 1.452 -0.279 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.6 -41.89 99.25 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.313 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -60.66 -40.98 94.05 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.463 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -85.85 140.83 30.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.436 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -71.76 140.24 49.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.487 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -76.31 142.91 41.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.515 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.18 -12.96 60.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.571 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -37.28 94.53 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -114.77 137.88 51.41 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.485 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.507 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 84.0 tt0 -86.82 116.38 24.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.268 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.507 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 80.7 mm-40 -130.55 131.24 44.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.316 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.512 179.911 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.41 152.77 30.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.623 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -61.82 -42.48 99.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.428 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -93.96 109.99 21.69 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.597 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 39.0 p30 -90.94 0.61 57.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.397 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' A' ' 376' ' ' LEU . 58.6 t30 -73.0 133.12 44.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.631 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 51.67 12.85 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.817 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.427 ' H ' ' C ' ' A' ' 374' ' ' ASN . 92.4 mt -133.5 135.39 44.42 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 8.8 p -169.83 77.8 0.65 Allowed Pre-proline 0 CA--C 1.531 0.233 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.564 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_exo -60.3 144.77 99.5 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.627 2.218 . . . . 0.0 112.012 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 381' ' ' VAL . 42.4 mm -65.64 -43.45 93.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.499 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -19.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.704 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.504 ' N ' ' O ' ' A' ' 379' ' ' ILE . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt -65.05 -42.25 94.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.45 -30.65 76.99 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.3 tp -61.38 -42.63 99.02 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.488 -179.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.59 144.68 28.48 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.524 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -77.0 127.66 33.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.07 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -75.92 130.56 38.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.268 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -72.85 139.66 47.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.729 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.32 -12.21 59.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.57 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.35 -37.33 94.66 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.066 -0.813 . . . . 0.0 111.066 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -104.72 134.68 47.46 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.744 0.307 . . . . 0.0 110.423 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -67.12 117.59 9.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.215 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -67.71 134.28 50.8 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.291 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.2 t80 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.56 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.5 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.38 96.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.556 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.549 ' CG ' ' H ' ' A' ' 372' ' ' ASP . 38.5 t0 -154.67 -140.25 0.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.418 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.549 ' H ' ' CG ' ' A' ' 371' ' ' ASP . 90.5 m-20 -64.86 139.02 58.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.467 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.03 -40.88 99.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.562 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -72.15 137.11 46.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.431 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -111.39 102.25 10.64 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.894 0.378 . . . . 0.0 110.382 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.457 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 10.0 mp -64.06 -42.28 97.06 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.455 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 47.57 59.12 17.01 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.558 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.73 162.27 43.15 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.797 2.331 . . . . 0.0 112.01 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.11 -43.08 98.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.392 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.06 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.794 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' A' ' 379' ' ' ILE . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.404 HD12 HG23 ' A' ' 398' ' ' ILE . 97.3 mt -64.96 -42.42 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.17 -35.5 92.06 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.48 -42.76 99.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 111.165 -179.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -73.77 134.6 43.46 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.675 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.2 t60 45.93 93.34 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.569 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -75.92 146.31 39.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.327 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -102.59 127.54 49.63 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.558 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.81 59.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.398 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.32 -36.08 92.76 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -85.53 129.02 34.92 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.808 0.337 . . . . 0.0 110.532 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.7 116.2 9.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.305 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -74.68 132.63 41.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.473 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.556 179.629 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 37.2 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.43 -38.45 91.21 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.622 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -96.57 108.58 21.2 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -68.62 141.93 55.27 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.492 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -66.83 143.32 56.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.543 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -63.33 -39.27 94.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.519 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -60.28 -44.02 95.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.479 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.542 ' N ' ' CD2' ' A' ' 376' ' ' LEU . 3.7 mm? -78.23 140.18 38.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.625 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 51.52 60.08 14.57 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.366 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -72.87 153.27 53.05 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.836 2.357 . . . . 0.0 112.008 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.7 mt -63.8 -43.16 97.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.25 179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.8 -19.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.592 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.526 ' N ' ' O ' ' A' ' 379' ' ' ILE . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.455 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.401 HG21 HD11 ' A' ' 390' ' ' ILE . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.408 HD11 HG21 ' A' ' 398' ' ' ILE . 97.6 mt -64.61 -42.75 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.34 -38.8 96.99 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.4 tp -62.8 -42.04 99.54 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.553 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 140.63 58.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.424 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -58.1 -41.68 84.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.616 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.0 t-80 -76.61 132.18 39.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.411 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -115.68 141.61 47.85 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.946 0.403 . . . . 0.0 110.452 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.98 -36.29 56.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.396 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -36.63 93.69 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.35 133.08 37.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 110.527 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -68.18 116.58 8.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.974 0.416 . . . . 0.0 110.415 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.64 144.25 14.3 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.639 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.568 179.594 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.21 143.65 21.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.336 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -99.78 111.67 23.98 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.581 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.43 -37.45 85.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.346 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 61.8 t0 -69.66 137.51 52.23 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.579 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.427 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 98.9 m-20 -68.94 141.76 54.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.443 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -148.57 121.12 8.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.319 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.486 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 8.8 mp -75.15 145.76 41.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.314 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.7 t -138.03 70.23 49.29 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.564 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -74.79 165.93 30.39 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.903 2.402 . . . . 0.0 112.072 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.6 mt -62.93 -42.86 98.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.358 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.34 -19.83 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.64 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.53 -41.49 83.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.41 -34.84 90.57 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.6 tp -62.43 -42.46 99.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.732 0.301 . . . . 0.0 110.664 -179.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.19 134.84 54.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.405 -179.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.2 t-80 -145.45 142.87 29.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -76.69 128.02 33.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.158 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -99.16 126.02 44.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.44 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.85 -11.64 59.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.546 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -35.89 92.7 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.21 135.61 47.38 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.862 0.363 . . . . 0.0 110.428 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.514 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 94.2 mt-10 -135.28 146.5 48.6 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.527 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.514 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 77.8 mm-40 -130.89 146.48 52.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.298 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.439 179.956 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -70.49 142.16 51.91 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.547 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -61.98 -42.56 99.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.51 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -89.01 110.09 20.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.545 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.06 140.25 56.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.326 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.62 ' ND2' ' CE2' ' A' ' 375' ' ' PHE . 65.9 t30 -151.92 169.74 21.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.465 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.62 ' CE2' ' ND2' ' A' ' 374' ' ' ASN . 92.7 m-85 41.38 92.99 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.556 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 377' ' ' VAL . 1.5 tp -53.87 -171.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 376' ' ' LEU . 7.2 m 31.31 69.07 0.75 Allowed Pre-proline 0 N--CA 1.468 0.427 0 O-C-N 123.532 0.52 . . . . 0.0 111.024 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -59.59 145.22 98.67 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.57 2.18 . . . . 0.0 111.874 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.533 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.8 mt -63.63 -43.31 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.11 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.51 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.615 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 379' ' ' ILE . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 398' ' ' ILE . 97.4 mt -65.07 -42.57 94.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . 0.499 ' O ' ' CE1' ' A' ' 402' ' ' HIS . . . -62.78 -33.02 85.69 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.7 tp -61.51 -43.0 99.65 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.343 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.78 148.46 22.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.499 ' CE1' ' O ' ' A' ' 399' ' ' GLY . 80.4 m80 -134.69 140.4 45.96 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.389 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -79.53 138.81 37.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.511 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -75.16 135.06 41.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.28 -11.7 59.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.597 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.09 -39.82 98.46 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -117.1 134.88 54.21 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.733 0.302 . . . . 0.0 110.363 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.28 149.02 49.71 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.568 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.91 146.53 10.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.489 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.474 -179.887 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.38 144.65 55.69 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.7 t0 -144.62 135.71 25.12 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.551 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 98.8 m-20 54.93 42.58 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.5 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -60.92 -39.19 88.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.442 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 38.9 p30 -151.58 162.55 40.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.422 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -66.97 -38.56 86.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.676 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.476 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.4 mp -78.2 143.39 37.21 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.452 ' O ' ' CG2' ' A' ' 377' ' ' VAL . 3.5 p 32.82 60.37 1.5 Allowed Pre-proline 0 CA--C 1.534 0.335 0 O-C-N 123.805 0.69 . . . . 0.0 111.059 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.406 ' O ' ' CG1' ' A' ' 381' ' ' VAL . 57.2 Cg_endo -71.89 147.12 49.11 Favored 'Trans proline' 0 C--N 1.3 -2.016 0 C-N-CA 122.125 1.884 . . . . 0.0 112.093 -178.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.473 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.22 -43.62 97.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.187 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -19.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.524 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.478 ' CG1' ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.478 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.4 HG22 HD11 ' A' ' 390' ' ' ILE . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt -63.61 -42.31 95.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.61 -34.98 91.34 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.9 tp -61.93 -42.18 98.81 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.494 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -67.87 137.65 55.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.524 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -65.74 -37.17 85.63 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.398 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.1 m170 -77.17 135.77 38.55 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.47 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -110.35 137.35 48.19 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.449 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.45 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.37 -40.5 97.87 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.039 -0.825 . . . . 0.0 111.039 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -117.35 141.15 48.67 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.816 0.341 . . . . 0.0 110.373 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.545 ' N ' ' OE1' ' A' ' 408' ' ' GLU . 56.1 mp0 -99.96 119.05 37.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.252 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -52.9 139.86 26.13 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.546 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.417 179.503 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.48 -37.72 88.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.517 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -94.49 109.64 21.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.349 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -86.69 113.41 22.53 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.515 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.413 ' O ' ' OD1' ' A' ' 373' ' ' ASP . 53.6 p-10 -66.24 144.21 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.518 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.575 HD21 ' CD1' ' A' ' 376' ' ' LEU . 65.5 t30 -79.67 151.98 30.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -90.8 89.01 7.3 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.482 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.575 ' CD1' HD21 ' A' ' 374' ' ' ASN . 90.2 mt -132.46 150.09 52.22 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.651 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.3 t 61.64 57.02 3.12 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.434 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -71.33 146.32 50.43 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.807 2.338 . . . . 0.0 112.041 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.3 mt -96.73 -74.7 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.447 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -92.26 -19.97 21.62 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.274 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.43 -42.42 93.39 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -24.1 62.58 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 57.1 tp -62.02 -41.49 98.14 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.374 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' A' ' 402' ' ' HIS . 98.8 mttt -61.96 -40.68 96.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.558 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 57.6 t-80 56.43 160.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . 0.52 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 80.1 m80 -106.17 124.85 50.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.419 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -105.19 125.16 50.67 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.487 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.39 -12.05 59.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.618 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.46 -38.7 96.76 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -109.72 136.01 49.73 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.844 0.355 . . . . 0.0 110.313 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.474 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 93.9 mt-10 -135.11 146.82 49.22 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.199 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.474 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 79.1 mm-40 -130.38 127.58 39.66 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.284 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.533 179.891 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.71 152.25 29.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.547 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.409 ' O ' ' O ' ' A' ' 374' ' ' ASN . 98.4 m-20 54.98 35.62 25.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.519 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.41 -19.53 63.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.621 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.98 -40.7 96.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.475 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' A' ' 371' ' ' ASP . 46.7 p-10 -153.92 166.45 32.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.401 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -136.9 113.14 9.87 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.333 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.478 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.4 mp -79.23 147.04 32.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.36 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.4 t 61.2 74.37 0.52 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.47 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.16 145.8 96.55 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 122.917 2.411 . . . . 0.0 112.039 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.5 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.2 -43.07 97.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.389 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.47 -20.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.576 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.41 HD12 HG23 ' A' ' 398' ' ' ILE . 97.8 mt -64.7 -42.62 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.67 92.31 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.1 tp -62.99 -41.87 99.69 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.797 0.332 . . . . 0.0 110.534 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.96 133.51 55.47 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.507 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -77.08 144.6 38.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -78.56 135.04 37.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.513 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -66.59 138.2 57.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.566 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.24 -11.3 59.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.633 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -36.86 93.99 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -77.47 129.58 35.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.543 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 409' ' ' GLN . 13.4 tm-20 -72.35 119.05 16.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.467 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.442 ' O ' ' OE1' ' A' ' 408' ' ' GLU . 6.9 pt20 -52.95 135.45 36.57 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.689 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.533 179.76 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 46.84 52.63 11.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -69.39 -18.88 63.81 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.704 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.83 -14.94 63.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.808 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -68.71 143.03 54.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 55.4 t30 -81.91 147.3 29.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.252 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -118.56 106.56 12.77 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.971 0.415 . . . . 0.0 110.26 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.6 mp -76.34 148.93 37.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.473 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.6 t 59.75 75.08 0.51 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.191 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.01 147.52 92.63 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.74 2.293 . . . . 0.0 111.628 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.3 mm -65.28 -43.44 95.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.541 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.07 -20.12 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.488 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 379' ' ' ILE . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.402 HD12 HG21 ' A' ' 390' ' ' ILE . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.44 -42.24 94.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.46 -32.88 82.72 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.418 ' O ' ' O ' ' A' ' 401' ' ' LYS . 0.2 OUTLIER -62.47 -42.34 99.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.422 -179.426 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 400' ' ' LEU . 86.6 tttt 58.09 154.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.533 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -61.48 -41.93 98.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.462 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.9 m80 -78.92 151.99 31.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.647 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -72.7 136.74 45.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.566 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.7 -12.53 59.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.598 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.55 -39.62 96.95 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -82.8 127.4 33.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.48 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -111.83 115.86 29.73 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.141 0.496 . . . . 0.0 110.593 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 3.5 pp0? -52.89 147.11 9.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.704 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 54.9 p90 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.629 179.716 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.99 -38.13 87.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.201 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -62.07 -41.7 98.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.28 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -68.28 143.66 55.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -85.88 110.16 19.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.423 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -72.48 139.74 47.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.205 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -90.77 0.79 57.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.107 0.48 . . . . 0.0 110.1 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.449 ' O ' ' C ' ' A' ' 377' ' ' VAL . 10.3 mp -94.88 127.02 40.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.006 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 376' ' ' LEU . 3.8 m 30.24 71.9 0.53 Allowed Pre-proline 0 N--CA 1.469 0.486 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.071 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -58.46 144.66 96.5 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.79 2.326 . . . . 0.0 111.901 -178.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.518 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.4 mm -65.35 -42.98 94.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.072 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.97 -19.53 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.401 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.518 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.477 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.9 -42.93 97.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.6 -38.81 96.46 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -63.68 -42.81 97.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.876 0.37 . . . . 0.0 110.063 -179.771 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.09 131.8 46.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.477 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.5 t60 45.63 84.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.402 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -88.21 126.45 35.16 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.523 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 61.2 t60 -88.62 126.52 35.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.53 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . 0.42 ' O ' ' OE2' ' A' ' 408' ' ' GLU . . . -77.32 -12.96 60.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.821 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.23 -35.07 91.51 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -101.31 137.57 39.48 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.93 0.395 . . . . 0.0 110.256 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.531 ' N ' ' OE1' ' A' ' 408' ' ' GLU . 55.3 mp0 -133.52 146.24 50.88 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.195 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.467 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 77.7 mm-40 -130.42 131.43 45.23 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.177 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.401 -179.928 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 45.7 m . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.81 109.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.518 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -61.85 -42.66 99.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.429 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.529 ' CG ' ' H ' ' A' ' 373' ' ' ASP . 45.4 t0 57.52 -176.76 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.554 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.529 ' H ' ' CG ' ' A' ' 372' ' ' ASP . 45.8 t0 58.9 37.69 24.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.502 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 100.0 m-20 -85.98 109.86 19.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.523 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.455 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 84.7 m-85 -81.77 -137.06 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.444 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.469 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.4 mp -83.23 141.53 31.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.091 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.434 ' C ' ' O ' ' A' ' 376' ' ' LEU . 2.3 p 32.41 74.35 0.48 Allowed Pre-proline 0 N--CA 1.466 0.354 0 CA-C-O 121.344 0.592 . . . . 0.0 110.991 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_exo -59.35 144.2 99.48 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.513 2.142 . . . . 0.0 111.7 -179.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -63.09 -43.12 98.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.917 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.06 -19.65 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.475 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.524 ' N ' ' O ' ' A' ' 379' ' ' ILE . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.443 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 390' ' ' ILE . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt -65.07 -42.48 94.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.76 -33.45 86.9 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.5 tp -61.81 -43.11 99.51 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.547 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -86.56 141.1 29.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.887 0.375 . . . . 0.0 110.639 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -147.65 142.59 26.93 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.466 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -74.27 137.9 43.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.404 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -84.55 140.95 31.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.718 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.05 59.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.691 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.57 -36.09 92.9 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -106.79 136.4 46.69 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.878 0.371 . . . . 0.0 110.534 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.504 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 81.0 tt0 -74.07 116.75 15.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.408 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.504 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 82.7 mm-40 -130.55 124.19 31.28 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.235 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.574 179.957 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.34 27.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.466 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -61.49 -41.37 97.17 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.281 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -63.22 -38.03 89.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.586 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.52 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 59.0 t0 57.89 42.01 23.76 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.617 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 60.0 t30 -76.0 117.93 18.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . 0.52 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 52.1 m-85 -87.66 82.44 7.4 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.852 0.358 . . . . 0.0 110.373 -179.494 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 5.8 mt -84.61 -44.53 13.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.075 0.464 . . . . 0.0 110.972 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.646 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -100.34 -39.43 0.23 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.532 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . 0.646 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 27.5 Cg_exo -59.11 146.48 94.24 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.313 2.008 . . . . 0.0 112.144 -179.178 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -66.28 -26.06 37.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.319 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.53 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.117 179.474 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.505 ' N ' ' O ' ' A' ' 379' ' ' ILE . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt -64.08 -42.75 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.53 -39.52 97.94 Favored Glycine 0 C--N 1.332 0.337 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.97 -42.61 99.88 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.585 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.93 135.53 51.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.658 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.1 p-80 -71.22 137.75 48.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.487 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -73.63 148.89 42.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.571 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -71.75 138.81 48.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.74 -12.77 60.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.567 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.41 -40.09 98.47 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -112.16 139.39 47.72 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.967 0.413 . . . . 0.0 110.482 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -70.76 116.36 10.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.441 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -52.66 135.8 34.18 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.546 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.539 179.545 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.05 153.92 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.536 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -96.07 110.13 22.43 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.33 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -89.81 111.53 22.58 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.514 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 38.7 p-10 -88.47 0.11 56.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.511 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.502 ' O ' ' N ' ' A' ' 376' ' ' LEU . 99.3 m-20 -74.25 142.58 45.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.433 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -57.33 83.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.251 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.502 ' N ' ' O ' ' A' ' 374' ' ' ASN . 6.9 tp -73.21 146.44 45.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.973 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 376' ' ' LEU . 5.9 m 31.74 70.11 0.72 Allowed Pre-proline 0 N--CA 1.467 0.409 0 O-C-N 123.39 0.431 . . . . 0.0 110.963 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -59.32 144.17 99.49 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.709 2.273 . . . . 0.0 112.18 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.76 -43.36 97.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.009 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.3 -19.76 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.604 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' A' ' 379' ' ' ILE . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.401 HD13 HG22 ' A' ' 390' ' ' ILE . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.73 -42.5 95.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.72 -32.87 85.07 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 55.3 tp -61.42 -42.72 99.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.745 0.307 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -88.14 143.65 26.93 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.745 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 73.1 m80 53.76 90.69 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.602 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -74.95 128.29 35.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -107.94 124.91 50.85 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.44 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.78 -12.63 59.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.53 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.22 -39.28 97.71 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -112.79 134.42 54.32 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.86 0.362 . . . . 0.0 110.48 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -101.89 116.01 31.79 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.297 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.502 ' CD ' ' N ' ' A' ' 409' ' ' GLN . 3.2 pm0 -130.44 146.73 52.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.3 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.554 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.59 151.76 24.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.512 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.0 t0 -147.25 131.64 17.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.617 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.432 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 55.5 t0 56.67 34.78 25.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.635 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' A' ' 376' ' ' LEU . 68.2 t0 -83.68 115.73 22.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.387 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . 0.413 ' OD1' ' O ' ' A' ' 374' ' ' ASN . 57.2 t-20 -64.79 -39.66 93.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.547 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -59.56 -46.64 88.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.558 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' A' ' 373' ' ' ASP . 8.9 mt -95.46 133.13 39.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.642 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 32.7 t 54.94 75.08 0.64 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.323 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -59.49 144.97 99.27 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.899 2.399 . . . . 0.0 112.02 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.486 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.7 mt -64.0 -42.99 97.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.469 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.97 -20.04 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.598 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.486 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.14 -42.44 95.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.96 -33.63 87.72 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' A' ' 401' ' ' LYS . 55.8 tp -63.13 -41.3 99.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.329 . . . . 0.0 110.643 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' A' ' 400' ' ' LEU . 88.7 tttt 51.67 103.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.556 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.13 138.77 45.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.666 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -99.9 127.55 46.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.31 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -104.17 133.44 49.08 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.479 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.91 -36.48 56.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.533 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.22 -40.62 98.14 Favored Glycine 0 CA--C 1.52 0.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -114.29 137.81 51.32 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.981 0.42 . . . . 0.0 110.555 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . 0.528 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 80.0 tt0 -85.08 115.7 23.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.351 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 75.1 mm-40 -130.9 146.68 52.39 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.953 0.406 . . . . 0.0 110.499 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . 0.402 ' OXT' ' NZ ' ' A' ' 401' ' ' LYS . 93.5 t80 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.576 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.35 -37.29 86.6 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.65 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.3 p30 -88.81 -1.41 58.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.595 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 372' ' ' ASP . . . . . 0.427 ' OD1' ' O ' ' A' ' 372' ' ' ASP . 68.1 t0 -64.24 -36.32 83.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.497 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.01 143.78 49.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.522 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 55.8 34.05 22.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -61.12 -42.24 98.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.462 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 376' ' ' LEU . . . . . 0.44 ' CD1' ' N ' ' A' ' 376' ' ' LEU . 9.5 mp -66.67 138.21 57.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.9 t 54.17 60.0 11.31 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -73.15 150.24 47.49 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.781 2.321 . . . . 0.0 112.127 -179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 379' ' ' ILE . . . . . 0.488 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -63.95 -42.89 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.486 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.07 -20.01 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.503 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 381' ' ' VAL . . . . . 0.488 ' N ' ' O ' ' A' ' 379' ' ' ILE . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 382' ' ' GLY . . . . . 0.474 ' N ' ' CG1' ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 390' ' ' ILE . . . . . 0.44 HD11 HG21 ' A' ' 390' ' ' ILE . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 398' ' ' ILE . . . . . 0.408 HG21 HD12 ' A' ' 398' ' ' ILE . 91.7 mt -63.58 -42.47 96.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -39.26 96.33 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -62.5 -42.37 99.45 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.155 0.502 . . . . 0.0 110.673 -179.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -65.55 138.58 58.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -57.39 -44.95 84.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.612 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -77.38 135.7 38.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.271 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -109.54 142.21 40.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.47 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.32 59.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.595 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.1 -38.75 96.42 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.056 -0.817 . . . . 0.0 111.056 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -77.84 136.41 38.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.579 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 70.6 mm-40 -135.3 147.52 49.21 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.029 0.442 . . . . 0.0 110.536 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 409' ' ' GLN . . . . . 0.518 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.0 pm0 -72.41 137.29 46.4 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.521 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.9 t80 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.531 179.381 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 120.587 0.232 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.165 0 CA-C-O 120.732 0.301 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.618 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.7 mt . . . . . 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.276 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.581 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.581 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.608 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.2 mt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.331 0 CA-C-O 120.607 0.242 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.606 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.334 0 CA-C-O 120.767 0.318 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.601 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.283 0 CA-C-O 120.475 0.178 . . . . 0.0 110.704 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.607 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 CA-C-O 120.586 0.231 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.609 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.509 0.195 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.546 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.628 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.743 0.306 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.263 0 CA-C-O 120.543 0.211 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.603 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.4 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.55 0.214 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.561 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.561 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.742 0.306 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.59 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.2 0 CA-C-O 120.796 0.331 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.402 ' O ' HD13 ' A' ' 389' ' ' LEU . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 389' ' ' LEU . . . . . 0.402 HD13 ' O ' ' A' ' 385' ' ' LEU . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.273 0 CA-C-O 120.636 0.255 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.563 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.563 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.346 0 CA-C-O 120.594 0.235 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.536 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.503 HG13 ' N ' ' A' ' 382' ' ' GLY . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.272 0 CA-C-O 120.594 0.235 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.583 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.817 0.342 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 385' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.692 0.282 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 381' ' ' VAL . . . . . 0.57 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 382' ' ' GLY . . . . . 0.57 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 388' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 392' ' ' VAL . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 392' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 388' ' ' VAL . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.7 mt . . . . . 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.37 139.74 49.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.51 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -153.52 173.79 15.26 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.855 0.359 . . . . 0.0 110.324 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -90.05 110.44 21.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.505 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -87.47 0.49 55.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.416 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -64.01 -41.09 97.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.55 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -63.64 -41.86 98.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.584 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.1 mp -81.07 137.85 35.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.389 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 18.5 t 44.06 73.33 0.98 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.528 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.13 144.21 99.47 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.897 2.398 . . . . 0.0 112.151 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.6 mt -64.42 -43.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.835 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.18 -41.36 89.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.78 -37.84 94.96 Favored Glycine 0 CA--C 1.519 0.314 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' A' ' 401' ' ' LYS . 41.6 tp -62.53 -42.5 99.56 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.8 tttt 59.2 140.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.694 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 65.9 t-80 -70.6 137.74 50.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.451 ' CD2' ' O ' ' A' ' 404' ' ' HIS . 82.0 t60 -75.25 134.49 41.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.506 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 404' ' ' HIS . . . . . 0.451 ' O ' ' CD2' ' A' ' 403' ' ' HIS . 76.3 m80 -68.56 140.17 55.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.479 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.74 -11.31 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.662 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -35.16 91.72 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.2 t80 -82.87 130.07 35.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.742 0.306 . . . . 0.0 110.49 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -85.22 115.93 23.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.454 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 50.1 tp60 -73.31 132.61 43.29 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.561 179.617 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.64 146.97 26.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.06 0.457 . . . . 0.0 110.515 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -61.58 -42.34 98.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.374 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 46.7 t0 56.3 40.18 29.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.425 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -68.15 144.47 54.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.506 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -86.53 109.7 19.28 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.573 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.412 ' CD1' ' O ' ' A' ' 376' ' ' LEU . 23.1 t80 -149.86 120.38 7.44 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.239 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.662 ' N ' HD12 ' A' ' 376' ' ' LEU . 8.2 mp -77.92 148.5 34.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.111 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' A' ' 376' ' ' LEU . 4.0 m 31.37 74.48 0.45 Allowed Pre-proline 0 N--CA 1.468 0.462 0 O-C-N 123.738 0.649 . . . . 0.0 111.009 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.35 145.57 98.36 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 122.917 2.412 . . . . 0.0 112.12 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.9 -42.97 97.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.256 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.05 -19.93 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.413 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.52 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.618 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.7 mt -63.71 -42.61 96.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -40.4 97.67 Favored Glycine 0 CA--C 1.521 0.419 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 45.8 tp -62.79 -41.9 99.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -74.28 139.1 44.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.45 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -150.2 144.1 25.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -81.03 128.66 33.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.273 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -99.28 137.82 37.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.458 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -13.34 59.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.583 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.82 -38.75 96.6 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.15 139.01 50.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.761 0.315 . . . . 0.0 110.537 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.89 118.74 23.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.22 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -52.79 138.69 28.7 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.543 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 86.2 t80 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.489 179.753 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.77 146.49 51.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.619 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.54 -45.18 95.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.157 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 68.1 t0 -67.92 133.67 49.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.477 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.479 ' CG ' ' H ' ' A' ' 374' ' ' ASN . 41.6 t0 56.36 -173.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.468 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.479 ' H ' ' CG ' ' A' ' 373' ' ' ASP . 98.8 m-20 55.05 39.46 31.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.473 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -81.74 83.26 7.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.691 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.9 mp -91.92 131.27 37.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.959 0.409 . . . . 0.0 110.332 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.441 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.6 t 56.52 54.28 7.93 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.521 ' O ' HG12 ' A' ' 381' ' ' VAL . 40.0 Cg_endo -66.76 152.48 80.47 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.824 2.35 . . . . 0.0 112.024 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.0 mt -64.94 -43.25 96.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.52 -19.67 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.276 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.581 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.581 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.608 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.2 mt -64.62 -42.55 95.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.91 -40.07 98.82 Favored Glycine 0 C--N 1.333 0.392 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 48.5 tp -62.73 -41.36 99.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.425 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -61.45 -41.27 96.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.593 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -151.37 136.21 17.25 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.415 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 83.4 t60 -74.14 129.2 37.37 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.443 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -76.61 127.88 33.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.3 -11.78 59.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.693 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.58 -35.84 92.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -83.11 132.99 35.08 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.733 0.302 . . . . 0.0 110.538 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -84.46 116.37 23.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.532 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.676 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.88 146.26 11.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.565 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.472 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 86.7 t80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.963 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.54 151.12 31.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.438 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -144.32 106.86 4.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.858 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 55.9 36.73 27.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.18 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 376' ' ' LEU . 47.9 t0 -63.66 -39.34 94.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.075 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.1 -39.55 94.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.754 0.312 . . . . 0.0 110.983 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -59.26 -44.72 92.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.755 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.449 ' O ' ' O ' ' A' ' 373' ' ' ASP . 10.6 mt -99.57 130.95 45.86 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.457 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.2 t 60.04 58.87 4.44 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.19 163.56 38.34 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.748 2.299 . . . . 0.0 112.057 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -62.36 -42.44 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.13 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.89 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.809 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.606 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.91 -42.49 94.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 399' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 403' ' ' HIS . . . -62.1 -33.29 85.3 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.2 tp -61.59 -42.39 98.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.339 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.5 ' C ' ' H ' ' A' ' 403' ' ' HIS . 99.4 mttt -98.21 151.74 20.13 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.362 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 28.5 t60 69.96 -38.65 0.41 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.708 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.5 ' H ' ' C ' ' A' ' 401' ' ' LYS . 98.5 m-70 -115.17 145.04 42.78 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -100.4 131.87 46.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.391 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -12.79 59.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.609 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.38 -40.26 97.65 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -88.52 128.18 35.55 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.738 0.304 . . . . 0.0 110.509 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -135.18 146.07 48.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.425 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.509 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 0.1 OUTLIER -130.46 146.7 52.06 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.509 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.502 ' OXT' ' CD1' ' A' ' 410' ' ' PHE . 54.5 p90 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.592 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 92.9 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -162.86 155.8 19.36 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.669 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -61.79 -41.96 98.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.418 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -86.31 111.68 20.69 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.467 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 67.5 t0 -66.41 136.06 55.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.487 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.483 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 46.7 p30 -155.29 167.11 31.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.227 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 45.6 t80 -145.69 121.81 10.78 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.203 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.9 mp -72.65 139.62 47.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.094 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 t 61.69 56.71 3.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.608 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.74 160.46 48.14 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.686 2.257 . . . . 0.0 112.031 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.5 mm -64.98 -42.06 93.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.323 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.91 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.448 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 379' ' ' ILE . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.601 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.42 -41.44 83.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.23 -32.26 83.52 Favored Glycine 0 N--CA 1.452 -0.279 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.6 -41.89 99.25 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.313 -179.076 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -60.66 -40.98 94.05 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.463 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -85.85 140.83 30.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.436 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -71.76 140.24 49.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.487 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -76.31 142.91 41.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.515 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.18 -12.96 60.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.571 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -37.28 94.53 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -114.77 137.88 51.41 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.485 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -86.82 116.38 24.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.268 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 22.7 mm100 -130.55 131.24 44.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.316 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.512 179.911 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.41 152.77 30.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.623 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -61.82 -42.48 99.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.428 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -93.96 109.99 21.69 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.597 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 39.0 p30 -90.94 0.61 57.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.397 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.412 ' C ' ' N ' ' A' ' 376' ' ' LEU . 58.6 t30 -73.0 133.12 44.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.631 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 51.67 12.85 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.817 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.412 ' N ' ' C ' ' A' ' 374' ' ' ASN . 92.4 mt -133.5 135.39 44.42 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 377' ' ' VAL . 8.8 p -169.83 77.8 0.65 Allowed Pre-proline 0 CA--C 1.531 0.233 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.564 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_exo -60.3 144.77 99.5 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.627 2.218 . . . . 0.0 112.012 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 381' ' ' VAL . 42.4 mm -65.64 -43.45 93.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.499 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -19.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.704 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.504 ' N ' ' O ' ' A' ' 379' ' ' ILE . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.607 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt -65.05 -42.25 94.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.45 -30.65 76.99 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.3 tp -61.38 -42.63 99.02 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.488 -179.553 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.59 144.68 28.48 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.524 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -77.0 127.66 33.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.07 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -75.92 130.56 38.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.268 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -72.85 139.66 47.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.729 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.32 -12.21 59.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.57 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.35 -37.33 94.66 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.066 -0.813 . . . . 0.0 111.066 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -104.72 134.68 47.46 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.744 0.307 . . . . 0.0 110.423 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -67.12 117.59 9.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.215 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -67.71 134.28 50.8 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.291 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.2 t80 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.56 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.5 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.38 96.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.556 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.509 ' CG ' ' H ' ' A' ' 372' ' ' ASP . 38.5 t0 -154.67 -140.25 0.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.418 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.509 ' H ' ' CG ' ' A' ' 371' ' ' ASP . 90.5 m-20 -64.86 139.02 58.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.467 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.03 -40.88 99.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.562 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -72.15 137.11 46.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.431 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -111.39 102.25 10.64 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.894 0.378 . . . . 0.0 110.382 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.0 mp -64.06 -42.28 97.06 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.455 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 47.57 59.12 17.01 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.558 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.73 162.27 43.15 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.797 2.331 . . . . 0.0 112.01 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.11 -43.08 98.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.392 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.06 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.794 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' A' ' 379' ' ' ILE . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.609 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.96 -42.42 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.17 -35.5 92.06 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.48 -42.76 99.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 111.165 -179.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -73.77 134.6 43.46 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.675 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.2 t60 45.93 93.34 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.569 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -75.92 146.31 39.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.327 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -102.59 127.54 49.63 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.558 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.81 59.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.398 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.32 -36.08 92.76 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -85.53 129.02 34.92 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.808 0.337 . . . . 0.0 110.532 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.7 116.2 9.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.305 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -74.68 132.63 41.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.473 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.556 179.629 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 37.2 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.43 -38.45 91.21 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.622 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -96.57 108.58 21.2 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -68.62 141.93 55.27 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.492 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -66.83 143.32 56.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.543 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -63.33 -39.27 94.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.519 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -60.28 -44.02 95.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.479 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.586 HD22 ' N ' ' A' ' 376' ' ' LEU . 3.7 mm? -78.23 140.18 38.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.625 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 51.52 60.08 14.57 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.366 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.53 ' O ' HG12 ' A' ' 381' ' ' VAL . 59.2 Cg_endo -72.87 153.27 53.05 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.836 2.357 . . . . 0.0 112.008 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.7 mt -63.8 -43.16 97.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.25 179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.8 -19.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.592 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.546 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.628 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.61 -42.75 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.34 -38.8 96.99 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.4 tp -62.8 -42.04 99.54 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.553 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 140.63 58.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.424 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -58.1 -41.68 84.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.616 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.0 t-80 -76.61 132.18 39.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.411 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -115.68 141.61 47.85 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.946 0.403 . . . . 0.0 110.452 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.98 -36.29 56.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.396 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -36.63 93.69 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.35 133.08 37.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 110.527 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -68.18 116.58 8.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.974 0.416 . . . . 0.0 110.415 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.64 144.25 14.3 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.639 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.568 179.594 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.21 143.65 21.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.336 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -99.78 111.67 23.98 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.581 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.43 -37.45 85.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.346 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 61.8 t0 -69.66 137.51 52.23 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.579 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.427 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 98.9 m-20 -68.94 141.76 54.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.443 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -148.57 121.12 8.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.319 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.652 ' N ' HD12 ' A' ' 376' ' ' LEU . 8.8 mp -75.15 145.76 41.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.314 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.7 t -138.03 70.23 49.29 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.564 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -74.79 165.93 30.39 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.903 2.402 . . . . 0.0 112.072 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.6 mt -62.93 -42.86 98.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.358 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.34 -19.83 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.64 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.53 -41.49 83.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.41 -34.84 90.57 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.6 tp -62.43 -42.46 99.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.732 0.301 . . . . 0.0 110.664 -179.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.19 134.84 54.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.405 -179.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.2 t-80 -145.45 142.87 29.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -76.69 128.02 33.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.158 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -99.16 126.02 44.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.44 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.85 -11.64 59.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.546 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -35.89 92.7 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.21 135.61 47.38 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.862 0.363 . . . . 0.0 110.428 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -135.28 146.5 48.6 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 21.2 mm100 -130.89 146.48 52.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.298 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.439 179.956 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -70.49 142.16 51.91 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.547 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -61.98 -42.56 99.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.51 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -89.01 110.09 20.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.545 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.06 140.25 56.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.326 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.62 ' ND2' ' CE2' ' A' ' 375' ' ' PHE . 65.9 t30 -151.92 169.74 21.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.465 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.62 ' CE2' ' ND2' ' A' ' 374' ' ' ASN . 92.7 m-85 41.38 92.99 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.556 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 377' ' ' VAL . 1.5 tp -53.87 -171.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 376' ' ' LEU . 7.2 m 31.31 69.07 0.75 Allowed Pre-proline 0 N--CA 1.468 0.427 0 O-C-N 123.532 0.52 . . . . 0.0 111.024 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -59.59 145.22 98.67 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.57 2.18 . . . . 0.0 111.874 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.533 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.8 mt -63.63 -43.31 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.11 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.51 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.615 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 379' ' ' ILE . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.603 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.4 mt -65.07 -42.57 94.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.78 -33.02 85.69 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.7 tp -61.51 -43.0 99.65 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.343 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.78 148.46 22.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 82.6 m-70 -134.69 140.4 45.96 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.389 -179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -79.53 138.81 37.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.511 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -75.16 135.06 41.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.28 -11.7 59.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.597 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.09 -39.82 98.46 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -117.1 134.88 54.21 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.733 0.302 . . . . 0.0 110.363 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.28 149.02 49.71 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.653 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.91 146.53 10.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.489 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.474 -179.887 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.38 144.65 55.69 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.7 t0 -144.62 135.71 25.12 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.551 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 98.8 m-20 54.93 42.58 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.5 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -60.92 -39.19 88.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.442 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 38.9 p30 -151.58 162.55 40.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.422 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -66.97 -38.56 86.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.676 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.63 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -78.2 143.39 37.21 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.684 ' O ' HG22 ' A' ' 377' ' ' VAL . 3.5 p 32.82 60.37 1.5 Allowed Pre-proline 0 CA--C 1.534 0.335 0 O-C-N 123.805 0.69 . . . . 0.0 111.059 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.54 ' O ' HG12 ' A' ' 381' ' ' VAL . 57.2 Cg_endo -71.89 147.12 49.11 Favored 'Trans proline' 0 C--N 1.3 -2.016 0 C-N-CA 122.125 1.884 . . . . 0.0 112.093 -178.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.473 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.22 -43.62 97.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.187 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -19.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.524 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.561 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.561 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt -63.61 -42.31 95.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.61 -34.98 91.34 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.9 tp -61.93 -42.18 98.81 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.494 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -67.87 137.65 55.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.524 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -65.74 -37.17 85.63 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.398 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.1 m170 -77.17 135.77 38.55 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.47 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -110.35 137.35 48.19 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.449 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.45 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.37 -40.5 97.87 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.039 -0.825 . . . . 0.0 111.039 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -117.35 141.15 48.67 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.816 0.341 . . . . 0.0 110.373 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.545 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.1 mp0 -99.96 119.05 37.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.252 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -52.9 139.86 26.13 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.546 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.417 179.503 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.48 -37.72 88.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.517 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -94.49 109.64 21.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.349 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -86.69 113.41 22.53 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.515 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 373' ' ' ASP . 53.6 p-10 -66.24 144.21 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.518 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -79.67 151.98 30.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.389 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -90.8 89.01 7.3 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.482 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 90.2 mt -132.46 150.09 52.22 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.651 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.3 t 61.64 57.02 3.12 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.434 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -71.33 146.32 50.43 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.807 2.338 . . . . 0.0 112.041 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.3 mt -96.73 -74.7 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.447 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -92.26 -19.97 21.62 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.274 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.43 -42.42 93.39 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -24.1 62.58 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 57.1 tp -62.02 -41.49 98.14 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.374 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' A' ' 402' ' ' HIS . 98.8 mttt -61.96 -40.68 96.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.558 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 402' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 57.6 t-80 56.43 160.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 403' ' ' HIS . . . . . 0.52 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 80.1 m80 -106.17 124.85 50.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.419 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -105.19 125.16 50.67 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.487 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.39 -12.05 59.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.618 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.46 -38.7 96.76 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -109.72 136.01 49.73 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.844 0.355 . . . . 0.0 110.313 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -135.11 146.82 49.22 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.199 179.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 21.8 mm100 -130.38 127.58 39.66 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.284 -179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.533 179.891 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.71 152.25 29.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.547 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.409 ' O ' ' O ' ' A' ' 374' ' ' ASN . 98.4 m-20 54.98 35.62 25.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.519 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.41 -19.53 63.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.621 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.98 -40.7 96.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.475 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' A' ' 371' ' ' ASP . 46.7 p-10 -153.92 166.45 32.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.401 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -136.9 113.14 9.87 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.333 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -79.23 147.04 32.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.36 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.4 t 61.2 74.37 0.52 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.47 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.16 145.8 96.55 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 122.917 2.411 . . . . 0.0 112.039 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.5 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.2 -43.07 97.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.389 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.47 -20.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.576 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.59 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.7 -42.62 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.67 92.31 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.1 tp -62.99 -41.87 99.69 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.797 0.332 . . . . 0.0 110.534 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.96 133.51 55.47 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.507 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -77.08 144.6 38.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -78.56 135.04 37.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.513 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -66.59 138.2 57.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.566 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.24 -11.3 59.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.633 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -36.86 93.99 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -77.47 129.58 35.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.543 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 409' ' ' GLN . 13.4 tm-20 -72.35 119.05 16.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.467 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.442 ' O ' ' OE1' ' A' ' 408' ' ' GLU . 6.9 pt20 -52.95 135.45 36.57 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.689 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.533 179.76 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 46.84 52.63 11.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -69.39 -18.88 63.81 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.704 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.83 -14.94 63.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.808 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -68.71 143.03 54.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 55.4 t30 -81.91 147.3 29.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.252 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -118.56 106.56 12.77 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.971 0.415 . . . . 0.0 110.26 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.6 mp -76.34 148.93 37.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.473 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.6 t 59.75 75.08 0.51 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.191 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.01 147.52 92.63 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.74 2.293 . . . . 0.0 111.628 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.3 mm -65.28 -43.44 95.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.541 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.07 -20.12 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.488 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 379' ' ' ILE . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.402 ' O ' HD13 ' A' ' 389' ' ' LEU . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 389' ' ' LEU . . . . . 0.402 HD13 ' O ' ' A' ' 385' ' ' LEU . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 396' ' ' TYR . . . . . 0.524 ' CZ ' HD23 ' A' ' 400' ' ' LEU . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.44 -42.24 94.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.46 -32.88 82.72 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.47 -42.34 99.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.422 -179.426 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 400' ' ' LEU . 86.6 tttt 58.09 154.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.533 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -61.48 -41.93 98.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.462 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.9 m80 -78.92 151.99 31.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.647 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -72.7 136.74 45.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.566 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.7 -12.53 59.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.598 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.55 -39.62 96.95 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -82.8 127.4 33.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.48 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -111.83 115.86 29.73 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.141 0.496 . . . . 0.0 110.593 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 3.5 pp0? -52.89 147.11 9.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.704 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 54.9 p90 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.629 179.716 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.99 -38.13 87.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.201 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -62.07 -41.7 98.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.28 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -68.28 143.66 55.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -85.88 110.16 19.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.423 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -72.48 139.74 47.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.205 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -90.77 0.79 57.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.107 0.48 . . . . 0.0 110.1 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.3 mp -94.88 127.02 40.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.006 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 376' ' ' LEU . 3.8 m 30.24 71.9 0.53 Allowed Pre-proline 0 N--CA 1.469 0.486 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.071 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.539 ' O ' HG12 ' A' ' 381' ' ' VAL . 31.8 Cg_exo -58.46 144.66 96.5 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.79 2.326 . . . . 0.0 111.901 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.518 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.4 mm -65.35 -42.98 94.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.072 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.97 -19.53 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.401 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.563 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.563 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 396' ' ' TYR . . . . . 0.613 ' CZ ' HD23 ' A' ' 400' ' ' LEU . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.9 -42.93 97.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.6 -38.81 96.46 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.613 HD23 ' CZ ' ' A' ' 396' ' ' TYR . 0.2 OUTLIER -63.68 -42.81 97.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.876 0.37 . . . . 0.0 110.063 -179.771 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.09 131.8 46.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.477 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.5 t60 45.63 84.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.402 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -88.21 126.45 35.16 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.523 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 14.4 t-80 -88.62 126.52 35.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.53 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 405' ' ' ALA . . . . . 0.42 ' O ' ' OE2' ' A' ' 408' ' ' GLU . . . -77.32 -12.96 60.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.821 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.23 -35.07 91.51 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -101.31 137.57 39.48 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.93 0.395 . . . . 0.0 110.256 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 408' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 55.3 mp0 -133.52 146.24 50.88 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.195 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 21.0 mm100 -130.42 131.43 45.23 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.177 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.401 -179.928 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 45.7 m . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.81 109.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.518 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -61.85 -42.66 99.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.429 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.5 ' CG ' ' H ' ' A' ' 373' ' ' ASP . 45.4 t0 57.52 -176.76 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.554 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.5 ' H ' ' CG ' ' A' ' 372' ' ' ASP . 45.8 t0 58.9 37.69 24.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.502 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 100.0 m-20 -85.98 109.86 19.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.523 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.455 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 84.7 m-85 -81.77 -137.06 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.444 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -83.23 141.53 31.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.091 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.589 ' O ' HG22 ' A' ' 377' ' ' VAL . 2.3 p 32.41 74.35 0.48 Allowed Pre-proline 0 N--CA 1.466 0.354 0 CA-C-O 121.344 0.592 . . . . 0.0 110.991 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.541 ' O ' HG12 ' A' ' 381' ' ' VAL . 39.3 Cg_exo -59.35 144.2 99.48 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.513 2.142 . . . . 0.0 111.7 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -63.09 -43.12 98.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.917 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.06 -19.65 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.475 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 378' ' ' PRO . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.536 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt -65.07 -42.48 94.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.76 -33.45 86.9 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.665 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.5 tp -61.81 -43.11 99.51 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.547 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -86.56 141.1 29.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.887 0.375 . . . . 0.0 110.639 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -147.65 142.59 26.93 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.466 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -74.27 137.9 43.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.404 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -84.55 140.95 31.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.718 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.05 59.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.691 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.57 -36.09 92.9 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -106.79 136.4 46.69 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.878 0.371 . . . . 0.0 110.534 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -74.07 116.75 15.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.408 179.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 23.5 mm100 -130.55 124.19 31.28 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.235 -179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.574 179.957 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.34 27.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.466 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -61.49 -41.37 97.17 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.281 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -63.22 -38.03 89.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.586 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.52 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 59.0 t0 57.89 42.01 23.76 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.617 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 60.0 t30 -76.0 117.93 18.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 375' ' ' PHE . . . . . 0.52 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 52.1 m-85 -87.66 82.44 7.4 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.852 0.358 . . . . 0.0 110.373 -179.494 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 5.8 mt -84.61 -44.53 13.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.075 0.464 . . . . 0.0 110.972 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.646 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -100.34 -39.43 0.23 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.532 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.646 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 27.5 Cg_exo -59.11 146.48 94.24 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.313 2.008 . . . . 0.0 112.144 -179.178 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -66.28 -26.06 37.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.319 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 380' ' ' ALA . . . . . 0.45 ' HB3' ' CD1' ' A' ' 375' ' ' PHE . . . -42.53 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.117 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.505 ' N ' ' O ' ' A' ' 379' ' ' ILE . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt -64.08 -42.75 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.53 -39.52 97.94 Favored Glycine 0 C--N 1.332 0.337 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.97 -42.61 99.88 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.585 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.93 135.53 51.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.658 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.1 p-80 -71.22 137.75 48.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.487 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -73.63 148.89 42.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.571 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -71.75 138.81 48.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.74 -12.77 60.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.567 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.41 -40.09 98.47 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -112.16 139.39 47.72 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.967 0.413 . . . . 0.0 110.482 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -70.76 116.36 10.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.441 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -52.66 135.8 34.18 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.546 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.539 179.545 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.05 153.92 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.536 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -96.07 110.13 22.43 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.33 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -89.81 111.53 22.58 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.514 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 38.7 p-10 -88.47 0.11 56.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.511 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.502 ' O ' ' N ' ' A' ' 376' ' ' LEU . 99.3 m-20 -74.25 142.58 45.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.433 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -57.33 83.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.251 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.502 ' N ' ' O ' ' A' ' 374' ' ' ASN . 6.9 tp -73.21 146.44 45.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.973 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 377' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 376' ' ' LEU . 5.9 m 31.74 70.11 0.72 Allowed Pre-proline 0 N--CA 1.467 0.409 0 O-C-N 123.39 0.431 . . . . 0.0 110.963 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -59.32 144.17 99.49 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.709 2.273 . . . . 0.0 112.18 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.76 -43.36 97.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.009 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.3 -19.76 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.604 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' A' ' 379' ' ' ILE . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.583 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.73 -42.5 95.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.72 -32.87 85.07 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 55.3 tp -61.42 -42.72 99.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.745 0.307 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -88.14 143.65 26.93 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.745 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 73.1 m80 53.76 90.69 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.602 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -74.95 128.29 35.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -107.94 124.91 50.85 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.44 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.78 -12.63 59.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.53 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.22 -39.28 97.71 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -112.79 134.42 54.32 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.86 0.362 . . . . 0.0 110.48 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -101.89 116.01 31.79 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.297 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.502 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 0.1 OUTLIER -130.44 146.73 52.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.923 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.3 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.554 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.59 151.76 24.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.512 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 371' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.0 t0 -147.25 131.64 17.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.617 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.432 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 55.5 t0 56.67 34.78 25.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.635 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' A' ' 376' ' ' LEU . 68.2 t0 -83.68 115.73 22.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.387 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 374' ' ' ASN . . . . . 0.413 ' OD1' ' O ' ' A' ' 374' ' ' ASN . 57.2 t-20 -64.79 -39.66 93.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.547 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -59.56 -46.64 88.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.558 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' A' ' 373' ' ' ASP . 8.9 mt -95.46 133.13 39.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.642 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 32.7 t 54.94 75.08 0.64 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.323 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -59.49 144.97 99.27 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.899 2.399 . . . . 0.0 112.02 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.486 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.7 mt -64.0 -42.99 97.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.469 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.97 -20.04 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.598 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.486 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 385' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.14 -42.44 95.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.96 -33.63 87.72 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' A' ' 401' ' ' LYS . 55.8 tp -63.13 -41.3 99.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.329 . . . . 0.0 110.643 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 401' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' A' ' 400' ' ' LEU . 88.7 tttt 51.67 103.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.556 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.13 138.77 45.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.666 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -99.9 127.55 46.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.31 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -104.17 133.44 49.08 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.479 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.91 -36.48 56.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.533 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.22 -40.62 98.14 Favored Glycine 0 CA--C 1.52 0.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.1 m-85 -114.29 137.81 51.32 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.981 0.42 . . . . 0.0 110.555 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -85.08 115.7 23.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.351 -179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 20.5 mm100 -130.9 146.68 52.39 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.953 0.406 . . . . 0.0 110.499 179.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 410' ' ' PHE . . . . . 0.402 ' OXT' ' NZ ' ' A' ' 401' ' ' LYS . 93.5 t80 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.576 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.35 -37.29 86.6 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.65 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.3 p30 -88.81 -1.41 58.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.595 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 372' ' ' ASP . . . . . 0.427 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 68.1 t0 -64.24 -36.32 83.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.497 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.01 143.78 49.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.522 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 55.8 34.05 22.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -61.12 -42.24 98.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.462 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 376' ' ' LEU . . . . . 0.607 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.5 mp -66.67 138.21 57.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.9 t 54.17 60.0 11.31 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 378' ' ' PRO . . . . . 0.504 ' O ' HG12 ' A' ' 381' ' ' VAL . 58.9 Cg_endo -73.15 150.24 47.49 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.781 2.321 . . . . 0.0 112.127 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 379' ' ' ILE . . . . . 0.488 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -63.95 -42.89 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.486 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.07 -20.01 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.503 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 381' ' ' VAL . . . . . 0.57 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 382' ' ' GLY . . . . . 0.57 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 388' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 392' ' ' VAL . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 392' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 388' ' ' VAL . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.7 mt -63.58 -42.47 96.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -39.26 96.33 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 400' ' ' LEU . . . . . 0.581 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.5 -42.37 99.45 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.155 0.502 . . . . 0.0 110.673 -179.622 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -65.55 138.58 58.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -57.39 -44.95 84.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.612 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -77.38 135.7 38.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.271 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -109.54 142.21 40.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.47 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.32 59.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.595 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.1 -38.75 96.42 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.056 -0.817 . . . . 0.0 111.056 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -77.84 136.41 38.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.579 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 70.6 mm-40 -135.3 147.52 49.21 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.029 0.442 . . . . 0.0 110.536 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 409' ' ' GLN . . . . . 0.59 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.0 pm0 -72.41 137.29 46.4 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.521 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.9 t80 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.531 179.381 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.178 0 CA-C-O 120.587 0.232 . . . . 0.0 110.835 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.165 0 CA-C-O 120.732 0.301 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.618 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.7 mt . . . . . 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.276 0 N-CA-C 110.276 -0.268 . . . . 0.0 110.276 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.581 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.581 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.608 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.2 mt . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.331 0 CA-C-O 120.607 0.242 . . . . 0.0 110.809 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.606 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.334 0 CA-C-O 120.767 0.318 . . . . 0.0 110.448 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.601 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.283 0 CA-C-O 120.475 0.178 . . . . 0.0 110.704 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.607 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt . . . . . 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.197 0 CA-C-O 120.586 0.231 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.609 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.169 0 CA-C-O 120.509 0.195 . . . . 0.0 110.592 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.546 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.628 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.743 0.306 . . . . 0.0 110.64 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm . . . . . 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.263 0 CA-C-O 120.543 0.211 . . . . 0.0 110.615 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.603 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.4 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.219 0 CA-C-O 120.55 0.214 . . . . 0.0 110.524 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.561 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.561 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.232 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.167 0 CA-C-O 120.742 0.306 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.59 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 0.2 0 CA-C-O 120.796 0.331 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.402 ' O ' HD13 ' A' ' 389' ' ' LEU . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . 0.402 HD13 ' O ' ' A' ' 385' ' ' LEU . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.273 0 CA-C-O 120.636 0.255 . . . . 0.0 110.401 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.563 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.563 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt . . . . . 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 0.346 0 CA-C-O 120.594 0.235 . . . . 0.0 110.475 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.536 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.536 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.503 HG13 ' N ' ' A' ' 382' ' ' GLY . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 0.272 0 CA-C-O 120.594 0.235 . . . . 0.0 110.604 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.583 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt . . . . . 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.817 0.342 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.692 0.282 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 381' ' ' VAL . . . . . 0.57 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 382' ' ' GLY . . . . . 0.57 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 388' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 392' ' ' VAL . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 392' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 388' ' ' VAL . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.7 mt . . . . . 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -71.37 139.74 49.92 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.51 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 54.3 p-10 -153.52 173.79 15.26 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 120.855 0.359 . . . . 0.0 110.324 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -90.05 110.44 21.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.505 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 34.6 p-10 -87.47 0.49 55.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.416 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 52.3 t30 -64.01 -41.09 97.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.55 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -63.64 -41.86 98.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.615 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.584 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.1 mp -81.07 137.85 35.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.389 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 18.5 t 44.06 73.33 0.98 Allowed Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.528 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_exo -59.13 144.21 99.47 Favored 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.897 2.398 . . . . 0.0 112.151 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.497 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.6 mt -64.42 -43.63 97.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.343 179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.14 -20.08 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.835 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' A' ' 379' ' ' ILE . 54.5 t -66.57 -43.27 90.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.697 0.284 . . . . 0.0 110.582 -179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.6 -39.45 97.59 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 111.054 -0.819 . . . . 0.0 111.054 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.83 -40.48 97.55 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.875 0.369 . . . . 0.0 110.481 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -37.28 87.01 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.601 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.591 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.33 -44.59 96.14 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.421 -179.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.77 -37.54 87.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.337 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.33 -42.9 99.02 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.8 t -64.79 -42.83 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 121.03 0.443 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 6.1 tt -60.61 -36.95 79.84 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.784 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.98 -41.97 94.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.92 0.39 . . . . 0.0 110.347 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.2 mt -60.49 -38.84 85.57 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.492 -179.529 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.75 -41.22 91.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.64 -41.44 97.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.984 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -61.55 -41.69 97.74 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.171 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -59.35 -41.11 88.44 Favored 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -65.19 -36.21 83.49 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.87 178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.8 t80 -57.84 -43.71 86.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.789 -0.642 . . . . 0.0 110.354 -179.28 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 44.7 mm -66.18 -41.36 89.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.584 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.78 -37.84 94.96 Favored Glycine 0 CA--C 1.519 0.314 0 N-CA-C 110.811 -0.916 . . . . 0.0 110.811 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.437 ' O ' ' O ' ' A' ' 401' ' ' LYS . 41.6 tp -62.53 -42.5 99.56 Favored 'General case' 0 C--N 1.326 -0.445 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.593 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.437 ' O ' ' O ' ' A' ' 400' ' ' LEU . 87.8 tttt 59.2 140.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.694 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 65.9 t-80 -70.6 137.74 50.26 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.66 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.451 ' CD2' ' O ' ' A' ' 404' ' ' HIS . 82.0 t60 -75.25 134.49 41.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.506 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . 0.451 ' O ' ' CD2' ' A' ' 403' ' ' HIS . 76.3 m80 -68.56 140.17 55.6 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.479 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.74 -11.31 59.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.662 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.08 -35.16 91.72 Favored Glycine 0 CA--C 1.524 0.594 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.2 t80 -82.87 130.07 35.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.742 0.306 . . . . 0.0 110.49 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -85.22 115.93 23.28 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.454 -179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 50.1 tp60 -73.31 132.61 43.29 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.473 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.561 179.617 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.64 146.97 26.2 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.06 0.457 . . . . 0.0 110.515 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 93.9 m-20 -61.58 -42.34 98.71 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.374 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 46.7 t0 56.3 40.18 29.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.425 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -68.15 144.47 54.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.506 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -86.53 109.7 19.28 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.573 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.412 ' CD1' ' O ' ' A' ' 376' ' ' LEU . 23.1 t80 -149.86 120.38 7.44 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-O 120.831 0.348 . . . . 0.0 110.239 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.662 ' N ' HD12 ' A' ' 376' ' ' LEU . 8.2 mp -77.92 148.5 34.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.111 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' A' ' 376' ' ' LEU . 4.0 m 31.37 74.48 0.45 Allowed Pre-proline 0 N--CA 1.468 0.462 0 O-C-N 123.738 0.649 . . . . 0.0 111.009 -179.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.35 145.57 98.36 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 C-N-CA 122.917 2.412 . . . . 0.0 112.12 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.9 -42.97 97.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.256 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.05 -19.93 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.413 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.52 ' N ' ' O ' ' A' ' 379' ' ' ILE . 55.8 t -65.24 -43.15 95.35 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.364 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.0 -179.756 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -64.14 -36.09 92.8 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 -179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.72 -40.92 98.7 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.82 0.343 . . . . 0.0 110.5 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.03 -36.91 85.88 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.586 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.618 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.12 -44.61 96.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.262 -179.258 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.54 -38.33 87.05 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.361 -179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.24 -44.98 96.93 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 77.4 t -68.11 -41.69 84.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-O 120.736 0.303 . . . . 0.0 110.84 -179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.575 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.44 -42.38 91.79 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.311 -178.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.8 mt -65.97 -41.98 90.88 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.583 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.2 mt -60.45 -40.13 90.03 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.476 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.3 t -63.81 -40.7 90.01 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.375 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.24 -40.91 95.81 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.814 -179.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.4 tt -61.82 -44.63 96.47 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.402 -0.519 . . . . 0.0 110.628 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.25 -36.13 82.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.423 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.1 t80 -60.2 -45.03 94.55 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.477 -179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -61.86 -43.68 98.36 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.541 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 95.7 mt -63.71 -42.61 96.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.545 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.48 -40.4 97.67 Favored Glycine 0 CA--C 1.521 0.419 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 45.8 tp -62.79 -41.9 99.47 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 120.869 0.366 . . . . 0.0 110.643 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -74.28 139.1 44.02 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.45 -179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 83.8 t60 -150.2 144.1 25.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.585 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -81.03 128.66 33.96 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.273 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -99.28 137.82 37.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.458 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.25 -13.34 59.96 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.583 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.82 -38.75 96.6 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.15 139.01 50.27 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.761 0.315 . . . . 0.0 110.537 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 44.2 tp10 -81.89 118.74 23.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.22 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -52.79 138.69 28.7 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.543 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 86.2 t80 . . . . . 0 C--N 1.325 -0.48 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.489 179.753 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 6.1 m . . . . . 0 N--CA 1.492 1.655 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -69.77 146.49 51.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.619 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 94.8 m-20 -61.54 -45.18 95.26 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.157 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' A' ' 373' ' ' ASP . 68.1 t0 -67.92 133.67 49.51 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.477 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.479 ' CG ' ' H ' ' A' ' 374' ' ' ASN . 41.6 t0 56.36 -173.87 0.06 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.468 179.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.479 ' H ' ' CG ' ' A' ' 373' ' ' ASP . 98.8 m-20 55.05 39.46 31.58 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.473 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -81.74 83.26 7.17 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.691 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.519 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.9 mp -91.92 131.27 37.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.959 0.409 . . . . 0.0 110.332 179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.441 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 3.6 t 56.52 54.28 7.93 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.374 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.521 ' O ' HG12 ' A' ' 381' ' ' VAL . 40.0 Cg_endo -66.76 152.48 80.47 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.824 2.35 . . . . 0.0 112.024 179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 65.0 mt -64.94 -43.25 96.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.415 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.52 -19.67 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.276 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.581 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.7 p -59.21 -44.6 92.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-O 120.755 0.312 . . . . 0.0 110.56 -179.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.581 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -64.63 -36.57 93.31 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.49 -40.37 95.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.855 0.359 . . . . 0.0 110.767 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.29 -46.3 89.36 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.651 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -66.91 -41.21 87.51 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.858 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.03 -38.79 92.36 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.324 -179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.35 -42.8 99.87 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.3 t -63.45 -43.09 98.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.936 0.398 . . . . 0.0 110.163 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.608 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.26 -38.02 85.19 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.171 -0.468 . . . . 0.0 109.956 -179.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.1 mm -62.92 -42.36 96.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.3 mt -61.18 -39.82 91.58 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.741 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 74.5 t -63.16 -41.43 92.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.316 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.66 -40.81 96.26 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.866 -179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.56 -41.98 99.26 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.778 -179.568 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.57 -49.22 77.1 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.926 0.393 . . . . 0.0 110.094 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -64.6 -35.08 79.84 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.424 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -56.93 -45.79 82.49 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.419 -179.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.2 mt -64.62 -42.55 95.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.392 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.91 -40.07 98.82 Favored Glycine 0 C--N 1.333 0.392 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 48.5 tp -62.73 -41.36 99.13 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.425 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -61.45 -41.27 96.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.593 -179.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -151.37 136.21 17.25 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.415 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 83.4 t60 -74.14 129.2 37.37 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.443 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 50.6 t60 -76.61 127.88 33.65 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.449 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.3 -11.78 59.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.693 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.58 -35.84 92.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.4 t80 -83.11 132.99 35.08 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.733 0.302 . . . . 0.0 110.538 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -84.46 116.37 23.05 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.532 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.676 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.88 146.26 11.08 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.565 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.472 ' OXT' ' CG ' ' A' ' 410' ' ' PHE . 86.7 t80 . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.963 -1.017 . . . . 0.0 110.653 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -151.54 151.12 31.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.438 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -144.32 106.86 4.41 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.858 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 55.9 36.73 27.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.18 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.449 ' O ' ' O ' ' A' ' 376' ' ' LEU . 47.9 t0 -63.66 -39.34 94.1 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.075 -179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.1 -39.55 94.3 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.754 0.312 . . . . 0.0 110.983 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -59.26 -44.72 92.4 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.755 -179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.449 ' O ' ' O ' ' A' ' 373' ' ' ASP . 10.6 mt -99.57 130.95 45.86 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.457 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.2 t 60.04 58.87 4.44 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.324 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -72.19 163.56 38.34 Favored 'Trans proline' 0 C--N 1.308 -1.595 0 C-N-CA 122.748 2.299 . . . . 0.0 112.057 -179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -62.36 -42.44 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.13 -179.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.89 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.809 179.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 46.5 t -66.55 -43.45 90.66 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.255 0 CA-C-O 120.616 0.246 . . . . 0.0 110.501 179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.48 -39.85 98.35 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.5 -39.67 94.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.884 0.373 . . . . 0.0 110.341 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.83 -37.0 86.15 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.612 179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.606 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.7 tt -62.04 -44.66 96.23 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.052 0.453 . . . . 0.0 110.184 -179.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.89 -37.71 88.41 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.735 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -60.58 -47.44 91.16 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 91.9 t -67.65 -41.89 85.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.664 0.269 . . . . 0.0 111.367 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.559 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.0 OUTLIER -60.14 -41.07 91.94 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 120.901 -0.32 . . . . 0.0 110.371 -178.444 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 94.5 mt -65.63 -42.07 91.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 120.814 0.34 . . . . 0.0 110.455 179.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -60.31 -41.06 92.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.494 -179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.9 t -63.86 -40.19 88.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.666 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.83 -41.31 95.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.283 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.32 -41.55 98.65 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.556 179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.14 -49.43 75.97 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.12 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 92.1 t80 -64.09 -35.95 82.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.221 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -57.24 -45.4 83.96 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.04 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.91 -42.49 94.95 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.534 179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 403' ' ' HIS . . . -62.1 -33.29 85.3 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.2 tp -61.59 -42.39 98.8 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.339 . . . . 0.0 110.228 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.5 ' C ' ' H ' ' A' ' 403' ' ' HIS . 99.4 mttt -98.21 151.74 20.13 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.362 -179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 28.5 t60 69.96 -38.65 0.41 Allowed 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.708 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.5 ' H ' ' C ' ' A' ' 401' ' ' LYS . 98.5 m-70 -115.17 145.04 42.78 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -100.4 131.87 46.09 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.391 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.17 -12.79 59.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.609 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.38 -40.26 97.65 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -88.52 128.18 35.55 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.738 0.304 . . . . 0.0 110.509 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -135.18 146.07 48.36 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.334 -0.394 . . . . 0.0 110.425 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.509 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 3.1 pm0 -130.46 146.7 52.06 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.509 -179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.502 ' OXT' ' CD1' ' A' ' 410' ' ' PHE . 54.5 p90 . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.592 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 92.9 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -162.86 155.8 19.36 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.669 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 -61.79 -41.96 98.39 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.418 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.4 t0 -86.31 111.68 20.69 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.467 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.483 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 67.5 t0 -66.41 136.06 55.2 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.487 179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.483 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 46.7 p30 -155.29 167.11 31.46 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.227 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 45.6 t80 -145.69 121.81 10.78 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.203 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.588 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.9 mp -72.65 139.62 47.44 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.094 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.7 t 61.69 56.71 3.06 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.608 -179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -67.74 160.46 48.14 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.686 2.257 . . . . 0.0 112.031 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.544 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.5 mm -64.98 -42.06 93.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.323 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.91 -19.88 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.448 179.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.544 ' N ' ' O ' ' A' ' 379' ' ' ILE . 41.6 t -66.15 -43.77 91.94 Favored 'Isoleucine or valine' 0 C--O 1.231 0.111 0 CA-C-O 120.763 0.316 . . . . 0.0 110.439 179.492 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' A' ' 379' ' ' ILE . . . -62.0 -41.04 99.64 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 -179.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.19 -39.9 95.97 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.868 0.366 . . . . 0.0 110.456 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.08 -36.47 84.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.577 179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.601 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.6 tt -61.88 -44.57 96.53 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.12 -179.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.5 -36.92 84.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.755 179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.94 -38.18 95.6 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 92.4 t -65.1 -42.22 93.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.971 0.415 . . . . 0.0 110.466 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.63 -36.98 77.42 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.389 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.6 -42.68 95.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.869 0.366 . . . . 0.0 110.33 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.0 mt -61.62 -41.99 98.26 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.665 -179.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.57 -40.83 90.42 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.758 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.4 -40.71 95.37 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.245 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.7 tt -61.71 -42.92 99.59 Favored 'General case' 0 C--N 1.318 -0.788 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.244 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.05 -35.84 81.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.685 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 3.1 m-85 -61.08 -42.68 98.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.428 -179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -61.8 -46.26 90.29 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.391 -179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.42 -41.44 83.36 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.539 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.23 -32.26 83.52 Favored Glycine 0 N--CA 1.452 -0.279 0 N-CA-C 110.728 -0.949 . . . . 0.0 110.728 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.551 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.6 -41.89 99.25 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.313 -179.076 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -60.66 -40.98 94.05 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.463 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 99.9 m-70 -85.85 140.83 30.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.436 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -71.76 140.24 49.41 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.487 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -76.31 142.91 41.13 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.515 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.18 -12.96 60.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.571 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.54 -37.28 94.53 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.089 -0.805 . . . . 0.0 111.089 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -114.77 137.88 51.41 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.824 0.345 . . . . 0.0 110.485 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.507 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 84.0 tt0 -86.82 116.38 24.86 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.268 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.507 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 80.7 mm-40 -130.55 131.24 44.94 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.316 179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 89.4 t80 . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.512 179.911 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 63.6 m . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.41 152.77 30.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.623 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -61.82 -42.48 99.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.428 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -93.96 109.99 21.69 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.597 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 39.0 p30 -90.94 0.61 57.47 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.397 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.412 ' C ' ' N ' ' A' ' 376' ' ' LEU . 58.6 t30 -73.0 133.12 44.16 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.631 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 51.67 12.85 0.19 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.817 179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.412 ' N ' ' C ' ' A' ' 374' ' ' ASN . 92.4 mt -133.5 135.39 44.42 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.615 HG13 ' O ' ' A' ' 377' ' ' VAL . 8.8 p -169.83 77.8 0.65 Allowed Pre-proline 0 CA--C 1.531 0.233 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.564 -179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_exo -60.3 144.77 99.5 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.627 2.218 . . . . 0.0 112.012 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.504 ' O ' ' N ' ' A' ' 381' ' ' VAL . 42.4 mm -65.64 -43.45 93.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.499 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.17 -19.73 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.704 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.504 ' N ' ' O ' ' A' ' 379' ' ' ILE . 50.9 t -66.4 -43.41 91.21 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 C-N-CA 121.025 -0.27 . . . . 0.0 110.463 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.41 -38.82 96.97 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.246 -0.741 . . . . 0.0 111.246 -179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.12 -39.77 95.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.915 0.388 . . . . 0.0 110.227 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.21 -36.9 85.62 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.752 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.607 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.0 tt -61.67 -43.82 98.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.989 0.423 . . . . 0.0 109.979 -179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.37 -37.57 87.78 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.649 179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.55 -40.55 98.83 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 96.6 t -64.33 -42.75 96.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.1 tt -60.42 -37.3 80.42 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.567 -179.633 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.7 mm -63.49 -42.2 95.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-O 120.883 0.373 . . . . 0.0 110.251 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -60.42 -40.06 89.66 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.369 -179.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 93.8 t -62.31 -40.75 89.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.69 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -60.86 -41.66 96.35 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.61 -179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.5 tt -62.26 -41.63 98.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.773 0.32 . . . . 0.0 110.453 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -57.06 -48.36 78.75 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.952 0.406 . . . . 0.0 110.031 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 94.0 t80 -64.64 -35.52 81.28 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.379 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.5 t80 -56.95 -45.61 82.7 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.237 -179.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt -65.05 -42.25 94.11 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.471 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.45 -30.65 76.99 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.3 tp -61.38 -42.63 99.02 Favored 'General case' 0 C--N 1.329 -0.301 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.488 -179.553 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.59 144.68 28.48 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.524 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 81.7 t60 -77.0 127.66 33.1 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.07 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.5 t60 -75.92 130.56 38.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.268 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -72.85 139.66 47.09 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.729 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.32 -12.21 59.92 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.57 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.35 -37.33 94.66 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 111.066 -0.813 . . . . 0.0 111.066 -179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -104.72 134.68 47.46 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.744 0.307 . . . . 0.0 110.423 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -67.12 117.59 9.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.215 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 48.4 tp60 -67.71 134.28 50.8 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.291 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.2 t80 . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.56 -179.974 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 21.5 m . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -62.7 -40.38 96.96 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.556 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.509 ' CG ' ' H ' ' A' ' 372' ' ' ASP . 38.5 t0 -154.67 -140.25 0.09 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.418 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.509 ' H ' ' CG ' ' A' ' 371' ' ' ASP . 90.5 m-20 -64.86 139.02 58.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.467 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -63.03 -40.88 99.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.562 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -72.15 137.11 46.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.431 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -111.39 102.25 10.64 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.894 0.378 . . . . 0.0 110.382 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.0 mp -64.06 -42.28 97.06 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.455 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 47.57 59.12 17.01 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.558 -179.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.73 162.27 43.15 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.797 2.331 . . . . 0.0 112.01 179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.534 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -63.11 -43.08 98.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.392 -179.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -40.87 -20.06 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.794 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.534 ' N ' ' O ' ' A' ' 379' ' ' ILE . 42.8 t -66.12 -43.36 92.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.285 0 CA-C-N 116.574 -0.285 . . . . 0.0 110.518 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.26 -38.88 97.17 Favored Glycine 0 CA--C 1.521 0.457 0 N-CA-C 111.378 -0.689 . . . . 0.0 111.378 -179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.93 92.57 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.024 0.44 . . . . 0.0 109.842 179.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.09 -36.83 85.29 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.639 -0.709 . . . . 0.0 110.027 179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.604 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.8 tt -62.25 -44.17 97.16 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.147 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.49 85.95 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.332 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.45 -40.86 99.62 Favored Glycine 0 CA--C 1.524 0.622 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 93.3 t -64.6 -42.39 94.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.919 0.39 . . . . 0.0 110.47 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.609 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -60.59 -37.79 82.52 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.837 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -63.0 -42.12 95.47 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.3 -179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -61.2 -40.3 93.44 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.768 -179.478 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 82.1 t -63.28 -39.93 87.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.387 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -61.62 -41.42 97.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.606 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.22 -41.94 98.84 Favored 'General case' 0 C--N 1.315 -0.902 0 C-N-CA 120.481 -0.488 . . . . 0.0 110.528 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.98 -48.94 74.91 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.948 0.404 . . . . 0.0 110.299 -179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 89.9 t80 -65.12 -34.44 78.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.927 -0.579 . . . . 0.0 110.378 179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.15 -45.83 83.25 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.326 -179.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -64.96 -42.42 94.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.453 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.17 -35.5 92.06 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 54.1 tp -62.48 -42.76 99.71 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.666 0.27 . . . . 0.0 111.165 -179.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 66.1 tttm -73.77 134.6 43.46 Favored 'General case' 0 C--N 1.328 -0.346 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.675 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.2 t60 45.93 93.34 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.569 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -75.92 146.31 39.78 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.327 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -102.59 127.54 49.63 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.558 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.26 -13.81 59.87 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.398 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.32 -36.08 92.76 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -85.53 129.02 34.92 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.808 0.337 . . . . 0.0 110.532 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.7 116.2 9.83 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.305 -179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -74.68 132.63 41.84 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.473 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 . . . . . 0 C--O 1.219 -0.517 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.556 179.629 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 37.2 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -63.43 -38.45 91.21 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.622 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -96.57 108.58 21.2 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.479 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -68.62 141.93 55.27 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.492 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -66.83 143.32 56.95 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.543 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -63.33 -39.27 94.08 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.519 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -60.28 -44.02 95.73 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.479 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.586 HD22 ' N ' ' A' ' 376' ' ' LEU . 3.7 mm? -78.23 140.18 38.9 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.625 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.8 t 51.52 60.08 14.57 Favored Pre-proline 0 C--N 1.327 -0.39 0 CA-C-N 115.909 -0.587 . . . . 0.0 110.366 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.53 ' O ' HG12 ' A' ' 381' ' ' VAL . 59.2 Cg_endo -72.87 153.27 53.05 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.836 2.357 . . . . 0.0 112.008 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.7 mt -63.8 -43.16 97.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.25 179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.8 -19.82 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.592 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.546 HG13 ' N ' ' A' ' 382' ' ' GLY . 9.2 p -60.11 -43.3 92.62 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.366 0 CA-C-O 120.749 0.309 . . . . 0.0 110.59 -179.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.546 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.1 -38.75 97.07 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.44 -41.87 97.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.877 0.37 . . . . 0.0 110.55 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.67 -37.56 86.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.493 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.628 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.9 tt -62.05 -44.68 96.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.183 0.516 . . . . 0.0 110.17 -179.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.07 -39.54 90.29 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.498 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.17 -44.37 94.07 Favored Glycine 0 CA--C 1.524 0.599 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.7 t -67.19 -42.18 87.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 120.947 0.403 . . . . 0.0 110.782 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.83 -40.67 84.86 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.926 -179.035 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.8 mt -67.74 -41.78 85.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.847 0.356 . . . . 0.0 110.408 179.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.3 mt -60.34 -40.73 91.71 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.732 -178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 71.8 t -63.67 -41.32 92.21 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.546 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.54 -41.45 97.37 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.925 -179.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.13 -41.63 98.45 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.628 -179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.21 -47.91 77.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.279 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.4 t80 -65.58 -34.59 78.6 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.359 179.56 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.4 t80 -57.55 -45.55 84.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.285 -179.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt -64.61 -42.75 96.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.406 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.34 -38.8 96.99 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 -179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 56.4 tp -62.8 -42.04 99.54 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.553 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 140.63 58.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.424 -179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -58.1 -41.68 84.06 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.616 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.0 t-80 -76.61 132.18 39.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.411 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.1 m80 -115.68 141.61 47.85 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.946 0.403 . . . . 0.0 110.452 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.98 -36.29 56.56 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.969 -0.559 . . . . 0.0 110.396 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -36.63 93.69 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -78.35 133.08 37.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 110.527 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -68.18 116.58 8.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.974 0.416 . . . . 0.0 110.415 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 6.3 pt20 -52.64 144.25 14.3 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.639 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.2 t80 . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.568 179.594 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 50.5 m . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.21 143.65 21.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.336 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 41.3 t0 -99.78 111.67 23.98 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.581 179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -62.43 -37.45 85.89 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.346 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 374' ' ' ASN . 61.8 t0 -69.66 137.51 52.23 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.579 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.427 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 98.9 m-20 -68.94 141.76 54.89 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.443 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 84.3 t80 -148.57 121.12 8.54 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.319 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.652 ' N ' HD12 ' A' ' 376' ' ' LEU . 8.8 mp -75.15 145.76 41.88 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.314 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 11.7 t -138.03 70.23 49.29 Favored Pre-proline 0 N--CA 1.464 0.261 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.564 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -74.79 165.93 30.39 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 C-N-CA 122.903 2.402 . . . . 0.0 112.072 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.536 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.6 mt -62.93 -42.86 98.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.358 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.34 -19.83 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.64 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.536 ' N ' ' O ' ' A' ' 379' ' ' ILE . 44.1 t -64.83 -43.1 96.41 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.321 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.461 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -61.08 -42.09 99.68 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 111.106 -0.798 . . . . 0.0 111.106 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -65.81 -39.35 90.81 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 120.735 0.302 . . . . 0.0 110.855 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.87 -45.14 95.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.098 0.475 . . . . 0.0 110.683 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -65.36 -41.53 93.71 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.209 179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.29 -38.16 82.75 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.519 -179.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.15 -39.17 96.03 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.117 -0.793 . . . . 0.0 111.117 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.0 t -63.67 -43.59 98.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.019 0.438 . . . . 0.0 110.698 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 7.2 mp -62.12 -37.57 85.62 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.377 -179.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.0 mm -62.5 -41.79 93.28 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.171 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.1 mt -60.83 -41.0 94.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.624 -179.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.4 t -65.14 -40.99 90.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.502 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.73 -40.88 96.63 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.749 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -62.0 -43.11 99.53 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.744 -179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -63.22 -35.74 81.34 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.524 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 91.8 t80 -60.69 -44.35 96.65 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -61.31 -47.43 85.96 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.893 -179.497 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 43.0 mm -68.53 -41.49 83.09 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.693 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.41 -34.84 90.57 Favored Glycine 0 N--CA 1.451 -0.329 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.6 tp -62.43 -42.46 99.47 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.732 0.301 . . . . 0.0 110.664 -179.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.19 134.84 54.57 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.405 -179.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 63.2 t-80 -145.45 142.87 29.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.578 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.5 t60 -76.69 128.02 33.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.158 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -99.16 126.02 44.85 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.44 179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.85 -11.64 59.91 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.546 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.18 -35.89 92.7 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 79.7 m-85 -106.21 135.61 47.38 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.862 0.363 . . . . 0.0 110.428 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.514 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 94.2 mt-10 -135.28 146.5 48.6 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.527 -179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.514 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 77.8 mm-40 -130.89 146.48 52.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.298 -179.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 91.6 m-85 . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.439 179.956 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 18.0 p . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -70.49 142.16 51.91 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.547 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -61.98 -42.56 99.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.51 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -89.01 110.09 20.84 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.545 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -68.06 140.25 56.28 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.326 -179.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.62 ' ND2' ' CE2' ' A' ' 375' ' ' PHE . 65.9 t30 -151.92 169.74 21.55 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.465 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.62 ' CE2' ' ND2' ' A' ' 374' ' ' ASN . 92.7 m-85 41.38 92.99 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.556 -179.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 377' ' ' VAL . 1.5 tp -53.87 -171.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.426 ' C ' ' O ' ' A' ' 376' ' ' LEU . 7.2 m 31.31 69.07 0.75 Allowed Pre-proline 0 N--CA 1.468 0.427 0 O-C-N 123.532 0.52 . . . . 0.0 111.024 -179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -59.59 145.22 98.67 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.57 2.18 . . . . 0.0 111.874 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.533 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.8 mt -63.63 -43.31 98.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.11 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.51 -19.83 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.615 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.533 ' N ' ' O ' ' A' ' 379' ' ' ILE . 47.0 t -65.82 -43.83 93.1 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.187 0 CA-C-O 120.667 0.27 . . . . 0.0 110.47 179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.3 -42.66 99.18 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 111.108 -0.797 . . . . 0.0 111.108 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.97 -40.09 94.47 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.769 0.318 . . . . 0.0 110.79 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.19 -45.01 95.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.646 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -66.09 -40.87 91.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.581 179.473 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.53 -39.25 90.37 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.691 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.1 -40.21 97.89 Favored Glycine 0 CA--C 1.526 0.736 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 97.8 t -64.53 -42.22 94.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.732 0.301 . . . . 0.0 110.601 179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.603 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -61.12 -37.5 83.01 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.99 -179.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -63.06 -42.42 96.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 N-CA-C 110.081 -0.341 . . . . 0.0 110.081 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.3 mt -60.65 -40.98 94.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.384 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 97.5 t -63.06 -40.44 89.04 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.654 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.5 mt -61.14 -41.22 96.35 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.574 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.0 tt -62.0 -41.94 98.61 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.841 0.353 . . . . 0.0 110.495 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.68 -48.99 74.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.197 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -65.95 -35.03 79.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.326 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 25.5 t80 -57.24 -45.91 83.5 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.275 -179.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.4 mt -65.07 -42.57 94.85 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.527 179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . 0.499 ' O ' ' CE1' ' A' ' 402' ' ' HIS . . . -62.78 -33.02 85.69 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 49.7 tp -61.51 -43.0 99.65 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.343 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -90.78 148.46 22.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.433 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.499 ' CE1' ' O ' ' A' ' 399' ' ' GLY . 80.4 m80 -134.69 140.4 45.96 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.389 -179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 54.7 p-80 -79.53 138.81 37.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.511 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -75.16 135.06 41.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.506 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.28 -11.7 59.86 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.597 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.09 -39.82 98.46 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -117.1 134.88 54.21 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.733 0.302 . . . . 0.0 110.363 179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 93.5 mt-10 -135.28 149.02 49.71 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.63 179.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.653 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.8 pm0 -52.91 146.53 10.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.489 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.474 -179.887 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 54.7 p . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -67.38 144.65 55.69 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.518 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.7 t0 -144.62 135.71 25.12 Favored 'General case' 0 N--CA 1.463 0.207 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.551 -179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 98.8 m-20 54.93 42.58 30.96 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.5 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -60.92 -39.19 88.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.442 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 38.9 p30 -151.58 162.55 40.79 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.422 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -66.97 -38.56 86.3 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.676 179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.63 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -78.2 143.39 37.21 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.839 -179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.684 ' O ' HG22 ' A' ' 377' ' ' VAL . 3.5 p 32.82 60.37 1.5 Allowed Pre-proline 0 CA--C 1.534 0.335 0 O-C-N 123.805 0.69 . . . . 0.0 111.059 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.54 ' O ' HG12 ' A' ' 381' ' ' VAL . 57.2 Cg_endo -71.89 147.12 49.11 Favored 'Trans proline' 0 C--N 1.3 -2.016 0 C-N-CA 122.125 1.884 . . . . 0.0 112.093 -178.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.473 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.22 -43.62 97.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.187 179.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.37 -19.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.524 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.561 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.8 p -58.96 -44.06 90.14 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 CA-C-O 120.708 0.29 . . . . 0.0 110.503 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.561 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.93 -42.4 98.35 Favored Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 -179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.53 -41.34 98.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -65.7 -37.48 86.58 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.358 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.2 tt -61.42 -45.5 94.05 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.221 -179.252 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.65 -36.7 81.54 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.23 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.82 -39.14 97.62 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 99.5 t -65.6 -41.79 91.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.903 0.382 . . . . 0.0 110.636 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.63 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.4 tt -59.13 -38.84 80.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.278 0.561 . . . . 0.0 109.67 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.8 mm -63.92 -42.75 96.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.502 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.4 mt -61.68 -40.68 95.85 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.621 -179.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 79.2 t -63.0 -40.36 88.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.378 -179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.1 mt -60.55 -41.39 94.45 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.46 -179.403 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -62.22 -43.42 98.88 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.599 -179.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.43 -36.82 83.75 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.703 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -60.42 -44.77 95.41 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.089 0.471 . . . . 0.0 110.639 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -61.55 -45.26 94.91 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.675 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 98.2 mt -63.61 -42.31 95.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.199 179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.61 -34.98 91.34 Favored Glycine 0 C--N 1.332 0.346 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 52.9 tp -61.93 -42.18 98.81 Favored 'General case' 0 C--N 1.327 -0.37 0 C-N-CA 120.875 -0.33 . . . . 0.0 110.494 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -67.87 137.65 55.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.524 -179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -65.74 -37.17 85.63 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.398 -179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 62.1 m170 -77.17 135.77 38.55 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.47 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -110.35 137.35 48.19 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.449 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.22 -12.91 60.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.45 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.37 -40.5 97.87 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 111.039 -0.825 . . . . 0.0 111.039 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -117.35 141.15 48.67 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-O 120.816 0.341 . . . . 0.0 110.373 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.545 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 56.1 mp0 -99.96 119.05 37.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.252 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.1 pt20 -52.9 139.86 26.13 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.546 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 94.5 t80 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.417 179.503 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 13.4 p . . . . . 0 N--CA 1.49 1.54 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -64.48 -37.72 88.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.517 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 70.7 m-20 -94.49 109.64 21.51 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.349 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -86.69 113.41 22.53 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.515 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.413 ' OD1' ' O ' ' A' ' 373' ' ' ASP . 53.6 p-10 -66.24 144.21 56.75 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.518 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.6 HD22 HD11 ' A' ' 376' ' ' LEU . 65.5 t30 -79.67 151.98 30.2 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.389 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -90.8 89.01 7.3 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.482 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.6 HD11 HD22 ' A' ' 374' ' ' ASN . 90.2 mt -132.46 150.09 52.22 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.651 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 4.3 t 61.64 57.02 3.12 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.434 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -71.33 146.32 50.43 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 C-N-CA 122.807 2.338 . . . . 0.0 112.041 -179.831 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . . . . . . . . . 96.3 mt -96.73 -74.7 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.447 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -92.26 -19.97 21.62 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.274 179.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . . . . . . . . . 56.1 t -68.15 -43.27 85.12 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.192 0 CA-C-O 120.686 0.279 . . . . 0.0 110.693 179.833 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.21 -39.45 97.92 Favored Glycine 0 CA--C 1.526 0.725 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.05 -40.27 95.91 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.76 0.314 . . . . 0.0 110.646 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.64 -46.23 89.18 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.472 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.1 mt -65.85 -40.26 91.55 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.037 -0.528 . . . . 0.0 110.556 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.59 -39.47 88.21 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.637 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.6 -40.14 95.84 Favored Glycine 0 CA--C 1.528 0.851 0 N-CA-C 111.154 -0.779 . . . . 0.0 111.154 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 87.7 t -65.5 -42.37 93.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.882 0.373 . . . . 0.0 110.691 -179.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.7 mt -62.55 -38.86 91.68 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.427 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 5.4 mm -62.55 -42.29 95.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.7 mt -60.84 -41.73 96.42 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.47 -179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 90.9 t -64.36 -41.84 93.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.698 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.2 mt -61.17 -40.96 95.85 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.665 -179.471 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -61.69 -42.01 98.36 Favored 'General case' 0 C--N 1.327 -0.393 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.451 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -58.79 -45.13 90.55 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.012 0.434 . . . . 0.0 110.018 179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -65.75 -33.85 76.81 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.131 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -57.67 -45.37 85.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.954 -179.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -65.43 -42.42 93.39 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.564 179.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.06 -24.1 62.58 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.445 -0.662 . . . . 0.0 111.445 -179.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 57.1 tp -62.02 -41.49 98.14 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.374 -179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.428 ' O ' ' O ' ' A' ' 402' ' ' HIS . 98.8 mttt -61.96 -40.68 96.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.558 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . 0.52 ' CE1' ' O ' ' A' ' 403' ' ' HIS . 57.6 t-80 56.43 160.43 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.288 179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . 0.52 ' O ' ' CE1' ' A' ' 402' ' ' HIS . 80.1 m80 -106.17 124.85 50.23 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.419 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -105.19 125.16 50.67 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.487 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -78.39 -12.05 59.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.618 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.46 -38.7 96.76 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -109.72 136.01 49.73 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.844 0.355 . . . . 0.0 110.313 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.474 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 93.9 mt-10 -135.11 146.82 49.22 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.199 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.474 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 79.1 mm-40 -130.38 127.58 39.66 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.284 -179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.533 179.891 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.564 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -154.71 152.25 29.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.547 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.409 ' O ' ' O ' ' A' ' 374' ' ' ASN . 98.4 m-20 54.98 35.62 25.04 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.519 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 -69.41 -19.53 63.8 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.621 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 94.4 m-20 -61.98 -40.7 96.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.475 179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.409 ' O ' ' O ' ' A' ' 371' ' ' ASP . 46.7 p-10 -153.92 166.45 32.93 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.401 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 t80 -136.9 113.14 9.87 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.333 -179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.61 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -79.23 147.04 32.72 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.36 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.4 t 61.2 74.37 0.52 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.47 -179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_exo -59.16 145.8 96.55 Favored 'Trans proline' 0 C--N 1.306 -1.68 0 C-N-CA 122.917 2.411 . . . . 0.0 112.039 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.5 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.4 mt -64.2 -43.07 97.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.389 179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.47 -20.1 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.576 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.5 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.0 t -66.44 -42.81 90.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.631 -179.724 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.65 -40.92 97.09 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -66.34 -36.31 82.57 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.761 0.315 . . . . 0.0 110.661 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.46 -45.83 91.25 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 121.142 0.496 . . . . 0.0 110.602 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.8 mt -65.44 -41.78 93.12 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.757 179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -63.16 -38.05 89.65 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.446 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.0 -40.04 98.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 89.3 t -64.2 -41.55 92.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.33 . . . . 0.0 110.461 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.59 HD23 ' O ' ' A' ' 389' ' ' LEU . 1.1 tt -59.94 -38.43 82.37 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.04 -179.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 34.0 mm -64.1 -42.67 96.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.408 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -61.27 -40.59 94.68 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.604 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.1 t -63.07 -40.7 90.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.453 -179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -41.51 96.9 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.774 -179.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.08 -42.56 99.33 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.627 -179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.33 -49.46 74.28 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.301 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.0 t80 -64.83 -34.73 79.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.435 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -57.2 -45.35 83.85 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.26 -179.394 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.8 mt -64.7 -42.62 95.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.448 179.705 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -63.88 -35.67 92.31 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 58.1 tp -62.99 -41.87 99.69 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.797 0.332 . . . . 0.0 110.534 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -61.96 133.51 55.47 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.507 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -77.08 144.6 38.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.54 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 85.2 t60 -78.56 135.04 37.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.513 -179.925 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 72.0 m80 -66.59 138.2 57.3 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.566 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -79.24 -11.3 59.95 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.633 -179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.21 -36.86 93.99 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -77.47 129.58 35.91 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.838 0.352 . . . . 0.0 110.543 -179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.442 ' OE1' ' O ' ' A' ' 409' ' ' GLN . 13.4 tm-20 -72.35 119.05 16.01 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.467 -179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.442 ' O ' ' OE1' ' A' ' 408' ' ' GLU . 6.9 pt20 -52.95 135.45 36.57 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.689 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 55.8 p90 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.533 179.76 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.5 t . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 46.84 52.63 11.27 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.594 179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 85.5 m-20 -69.39 -18.88 63.81 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.704 -179.742 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -66.83 -14.94 63.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.808 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -68.71 143.03 54.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 55.4 t30 -81.91 147.3 29.35 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.252 179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -118.56 106.56 12.77 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-O 120.971 0.415 . . . . 0.0 110.26 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.6 mp -76.34 148.93 37.12 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.473 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 3.6 t 59.75 75.08 0.51 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.191 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_exo -60.01 147.52 92.63 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.74 2.293 . . . . 0.0 111.628 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.508 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.3 mm -65.28 -43.44 95.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.541 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.07 -20.12 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.488 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.508 ' N ' ' O ' ' A' ' 379' ' ' ILE . 70.9 t -67.18 -42.48 88.1 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.835 -179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -59.95 -44.04 97.54 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 110.516 -1.033 . . . . 0.0 110.516 -179.373 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.95 -38.76 92.03 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.937 -0.305 . . . . 0.0 110.44 179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.82 -46.28 91.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.2 0.524 . . . . 0.0 110.516 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.402 ' O ' HD13 ' A' ' 389' ' ' LEU . 4.9 mt -64.71 -41.85 95.69 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.613 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.13 -36.45 77.51 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.523 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.82 -40.09 95.42 Favored Glycine 0 CA--C 1.522 0.506 0 N-CA-C 110.996 -0.842 . . . . 0.0 110.996 179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.76 -43.86 96.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.035 0.445 . . . . 0.0 110.866 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . 0.402 HD13 ' O ' ' A' ' 385' ' ' LEU . 7.3 mp -61.1 -41.91 97.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.672 -179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 88.3 mt -67.2 -41.32 86.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.196 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.5 mt -59.77 -42.14 92.66 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.875 -178.908 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 85.8 t -63.79 -40.78 90.32 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.082 0.468 . . . . 0.0 110.359 -179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.9 mt -61.16 -42.02 97.81 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.646 -179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.6 tt -63.24 -41.48 99.08 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.716 -179.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.3 -49.13 72.95 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.86 0.362 . . . . 0.0 110.362 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . 0.524 ' CZ ' HD23 ' A' ' 400' ' ' LEU . 86.1 t80 -63.41 -36.45 83.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.348 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -56.45 -45.35 80.87 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.216 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.5 mt -64.44 -42.24 94.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.642 179.64 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.46 -32.88 82.72 Favored Glycine 0 C--N 1.332 0.359 0 N-CA-C 110.846 -0.902 . . . . 0.0 110.846 -179.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.47 -42.34 99.41 Favored 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 120.601 -0.44 . . . . 0.0 110.422 -179.426 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.418 ' O ' ' O ' ' A' ' 400' ' ' LEU . 86.6 tttt 58.09 154.17 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.533 -179.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.6 t60 -61.48 -41.93 98.01 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.462 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 80.9 m80 -78.92 151.99 31.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.647 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.4 m80 -72.7 136.74 45.64 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.566 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.7 -12.53 59.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.598 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.55 -39.62 96.95 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 88.3 t80 -82.8 127.4 33.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.691 0.281 . . . . 0.0 110.48 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -111.83 115.86 29.73 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 121.141 0.496 . . . . 0.0 110.593 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 3.5 pp0? -52.89 147.11 9.58 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.704 179.714 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 54.9 p90 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.629 179.716 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -61.99 -38.13 87.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.201 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.9 m-20 -62.07 -41.7 98.44 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.28 -179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 88.6 m-20 -68.28 143.66 55.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.46 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 67.6 t0 -85.88 110.16 19.22 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.423 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -72.48 139.74 47.82 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.205 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -90.77 0.79 57.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 121.107 0.48 . . . . 0.0 110.1 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.571 ' N ' HD12 ' A' ' 376' ' ' LEU . 10.3 mp -94.88 127.02 40.6 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.006 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.449 ' C ' ' O ' ' A' ' 376' ' ' LEU . 3.8 m 30.24 71.9 0.53 Allowed Pre-proline 0 N--CA 1.469 0.486 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.071 179.868 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.539 ' O ' HG12 ' A' ' 381' ' ' VAL . 31.8 Cg_exo -58.46 144.66 96.5 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 C-N-CA 122.79 2.326 . . . . 0.0 111.901 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.518 ' O ' ' N ' ' A' ' 381' ' ' VAL . 43.4 mm -65.35 -42.98 94.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.072 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -41.97 -19.53 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.401 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.563 HG13 ' N ' ' A' ' 382' ' ' GLY . 7.0 p -60.71 -44.02 96.31 Favored 'Isoleucine or valine' 0 C--O 1.231 0.128 0 CA-C-O 120.792 0.329 . . . . 0.0 110.556 -179.821 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.563 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.41 -40.36 98.77 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.84 -37.8 88.82 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.751 0.31 . . . . 0.0 110.642 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -60.59 -46.27 90.88 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.624 -179.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.0 mt -66.26 -41.1 90.41 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.47 179.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.53 -37.69 87.09 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.452 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.84 -43.26 97.89 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.09 -42.1 87.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 CA-C-O 120.765 0.317 . . . . 0.0 110.827 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -59.52 -41.14 89.27 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.719 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 93.2 mt -67.05 -42.23 88.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.834 0.35 . . . . 0.0 110.475 179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.2 mt -59.81 -41.57 91.53 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.914 -179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 92.1 t -64.08 -41.93 94.01 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.896 179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.37 -41.88 97.81 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.713 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.8 tt -62.42 -41.46 98.72 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.82 0.343 . . . . 0.0 110.524 -179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.48 -49.06 73.54 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.176 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . 0.613 ' CZ ' HD23 ' A' ' 400' ' ' LEU . 92.6 t80 -64.55 -35.99 82.76 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.276 179.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 23.7 t80 -57.59 -45.19 85.59 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.318 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.3 mt -63.9 -42.93 97.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.4 179.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -61.6 -38.81 96.46 Favored Glycine 0 CA--C 1.521 0.461 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.613 HD23 ' CZ ' ' A' ' 396' ' ' TYR . 0.2 OUTLIER -63.68 -42.81 97.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.876 0.37 . . . . 0.0 110.063 -179.771 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 52.5 tttp -67.09 131.8 46.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.477 -179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.5 t60 45.63 84.03 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.402 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 78.4 t60 -88.21 126.45 35.16 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.523 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 61.2 t60 -88.62 126.52 35.33 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.53 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . 0.42 ' O ' ' OE2' ' A' ' 408' ' ' GLU . . . -77.32 -12.96 60.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.821 -179.832 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.23 -35.07 91.51 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.015 -0.834 . . . . 0.0 111.015 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -101.31 137.57 39.48 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 120.93 0.395 . . . . 0.0 110.256 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.531 ' OE1' ' N ' ' A' ' 408' ' ' GLU . 55.3 mp0 -133.52 146.24 50.88 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.195 -179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.467 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 77.7 mm-40 -130.42 131.43 45.23 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.177 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.401 -179.928 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 45.7 m . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . 61.81 109.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.518 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -61.85 -42.66 99.32 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.429 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.5 ' CG ' ' H ' ' A' ' 373' ' ' ASP . 45.4 t0 57.52 -176.76 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.554 179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.5 ' H ' ' CG ' ' A' ' 372' ' ' ASP . 45.8 t0 58.9 37.69 24.66 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.502 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 100.0 m-20 -85.98 109.86 19.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.523 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.455 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 84.7 m-85 -81.77 -137.06 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.444 -179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.613 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.4 mp -83.23 141.53 31.81 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.091 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.589 ' O ' HG22 ' A' ' 377' ' ' VAL . 2.3 p 32.41 74.35 0.48 Allowed Pre-proline 0 N--CA 1.466 0.354 0 CA-C-O 121.344 0.592 . . . . 0.0 110.991 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.541 ' O ' HG12 ' A' ' 381' ' ' VAL . 39.3 Cg_exo -59.35 144.2 99.48 Favored 'Trans proline' 0 C--N 1.304 -1.781 0 C-N-CA 122.513 2.142 . . . . 0.0 111.7 -179.258 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.3 mt -63.09 -43.12 98.78 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.917 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.06 -19.65 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.346 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.475 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 378' ' ' PRO . 7.9 p -60.48 -42.89 92.92 Favored 'Isoleucine or valine' 0 C--O 1.231 0.119 0 CA-C-O 120.773 0.32 . . . . 0.0 110.48 -179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.536 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -63.19 -37.19 94.5 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.971 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.76 -39.47 94.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.737 0.303 . . . . 0.0 110.665 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.68 -46.09 89.75 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.542 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.3 mt -66.07 -40.52 90.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.596 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -61.85 -38.1 86.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.514 -179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -65.34 -43.7 94.66 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 61.1 t -65.81 -42.27 91.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.816 0.341 . . . . 0.0 111.137 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.4 mt -62.13 -42.41 99.2 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.469 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 91.6 mt -65.55 -41.93 91.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-O 120.815 0.341 . . . . 0.0 110.321 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.5 mt -59.87 -41.93 92.62 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.71 -179.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.66 -41.88 93.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.93 179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.3 mt -61.47 -41.43 97.24 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.73 -179.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.1 tt -62.19 -41.5 98.4 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.491 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.08 -48.8 75.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.941 0.401 . . . . 0.0 110.067 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -65.34 -35.03 79.73 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.367 179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -57.02 -45.9 82.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.28 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.6 mt -65.07 -42.48 94.64 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.367 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.76 -33.45 86.9 Favored Glycine 0 CA--C 1.523 0.568 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 -179.665 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 47.5 tp -61.81 -43.11 99.51 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.773 -0.371 . . . . 0.0 110.547 -179.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -86.56 141.1 29.28 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.887 0.375 . . . . 0.0 110.639 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -147.65 142.59 26.93 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.466 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -74.27 137.9 43.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.404 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -84.55 140.95 31.07 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.718 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.3 -12.05 59.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.691 179.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.57 -36.09 92.9 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -106.79 136.4 46.69 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.878 0.371 . . . . 0.0 110.534 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.504 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 81.0 tt0 -74.07 116.75 15.06 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.408 179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.504 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 82.7 mm-40 -130.55 124.19 31.28 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.235 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.574 179.957 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 32.4 m . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -150.63 147.34 27.28 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.466 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.4 m-20 -61.49 -41.37 97.17 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.281 -179.666 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -63.22 -38.03 89.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.586 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.52 ' OD1' ' CZ ' ' A' ' 375' ' ' PHE . 59.0 t0 57.89 42.01 23.76 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.617 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 60.0 t30 -76.0 117.93 18.24 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.373 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . 0.52 ' CZ ' ' OD1' ' A' ' 373' ' ' ASP . 52.1 m-85 -87.66 82.44 7.4 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-O 120.852 0.358 . . . . 0.0 110.373 -179.494 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . . . . . . . . . 5.8 mt -84.61 -44.53 13.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.075 0.464 . . . . 0.0 110.972 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.646 ' N ' ' CD ' ' A' ' 378' ' ' PRO . 0.3 OUTLIER -100.34 -39.43 0.23 Allowed Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.532 179.998 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.646 ' CD ' ' N ' ' A' ' 377' ' ' VAL . 27.5 Cg_exo -59.11 146.48 94.24 Favored 'Trans proline' 0 N--CA 1.493 1.49 0 C-N-CA 122.313 2.008 . . . . 0.0 112.144 -179.178 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.505 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -66.28 -26.06 37.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.319 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . 0.45 ' HB3' ' CD1' ' A' ' 375' ' ' PHE . . . -42.53 -20.06 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.117 179.474 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.505 ' N ' ' O ' ' A' ' 379' ' ' ILE . 14.9 p -60.33 -39.95 82.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 120.879 0.371 . . . . 0.0 110.193 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.503 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -59.34 -42.2 97.28 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -64.87 -37.81 88.88 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.79 0.329 . . . . 0.0 110.734 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -62.39 -44.93 95.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.706 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 4.9 mt -65.39 -39.85 92.73 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.647 179.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -60.78 -40.07 91.17 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.02 -0.537 . . . . 0.0 110.419 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.67 -36.76 93.52 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.069 -0.812 . . . . 0.0 111.069 179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 88.7 t -64.01 -42.18 94.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 120.915 0.388 . . . . 0.0 110.577 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.2 mt -62.52 -39.16 92.66 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.28 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 32.3 mm -63.85 -42.05 94.58 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 10.0 mt -61.07 -40.95 95.64 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.329 -179.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 70.3 t -64.12 -40.67 89.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.61 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.0 mt -61.49 -41.32 97.08 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.5 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.5 tt -62.2 -41.67 98.59 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.584 -179.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -55.23 -49.17 72.67 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.933 0.397 . . . . 0.0 110.271 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -63.12 -36.05 82.31 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.44 179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -57.23 -45.11 84.21 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.292 -179.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.9 mt -64.08 -42.75 96.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.601 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.53 -39.52 97.94 Favored Glycine 0 C--N 1.332 0.337 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 51.2 tp -62.97 -42.61 99.88 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.585 -179.755 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -68.93 135.53 51.16 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.658 -179.316 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 54.1 p-80 -71.22 137.75 48.92 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.487 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 49.6 t-80 -73.63 148.89 42.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.571 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -71.75 138.81 48.74 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.548 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.74 -12.77 60.0 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.567 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.41 -40.09 98.47 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -112.16 139.39 47.72 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.967 0.413 . . . . 0.0 110.482 179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -70.76 116.36 10.98 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.441 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . . . . . . . . . 9.8 pt20 -52.66 135.8 34.18 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.546 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.965 -1.017 . . . . 0.0 110.539 179.545 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 98.0 p . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.337 -0.616 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.05 153.92 28.7 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.536 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 87.7 m-20 -96.07 110.13 22.43 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.33 179.89 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -89.81 111.53 22.58 Favored 'General case' 0 C--N 1.333 -0.139 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.514 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.406 ' N ' ' OD1' ' A' ' 373' ' ' ASP . 38.7 p-10 -88.47 0.11 56.62 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.511 -179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.502 ' O ' ' N ' ' A' ' 376' ' ' LEU . 99.3 m-20 -74.25 142.58 45.29 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.433 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -57.33 83.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.251 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.502 ' N ' ' O ' ' A' ' 374' ' ' ASN . 6.9 tp -73.21 146.44 45.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.973 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 376' ' ' LEU . 5.9 m 31.74 70.11 0.72 Allowed Pre-proline 0 N--CA 1.467 0.409 0 O-C-N 123.39 0.431 . . . . 0.0 110.963 -179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_exo -59.32 144.17 99.49 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.709 2.273 . . . . 0.0 112.18 -179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.509 ' O ' ' N ' ' A' ' 381' ' ' VAL . 97.1 mt -63.76 -43.36 97.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.009 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.3 -19.76 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.272 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.604 179.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.509 ' N ' ' O ' ' A' ' 379' ' ' ILE . 59.8 t -66.51 -43.53 90.75 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 121.004 -0.278 . . . . 0.0 110.42 179.734 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -63.76 -37.67 95.05 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.28 -38.85 92.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.947 0.404 . . . . 0.0 110.206 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.33 -37.71 88.47 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.441 179.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.583 HD23 ' O ' ' A' ' 385' ' ' LEU . 1.4 tt -62.48 -43.09 99.66 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 116.124 -0.489 . . . . 0.0 109.982 -179.404 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.17 -35.99 80.52 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.08 179.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -61.65 -40.08 98.27 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.3 t -63.73 -43.69 98.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.699 0.285 . . . . 0.0 110.894 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 4.6 mt -62.58 -42.48 99.58 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.229 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 92.8 mt -65.7 -41.56 90.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.776 0.322 . . . . 0.0 110.163 179.229 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.26 -41.68 89.41 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.554 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 72.3 t -64.47 -41.97 93.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.829 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 6.4 mt -61.55 -41.45 97.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.771 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 6.3 tt -62.27 -41.65 98.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.652 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -56.62 -49.23 75.57 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 93.1 t80 -64.72 -35.65 81.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.247 179.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -57.44 -45.62 84.48 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.36 -179.39 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 97.7 mt -64.73 -42.5 95.15 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.212 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.359 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.72 -32.87 85.07 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . . . . . . . . . 55.3 tp -61.42 -42.72 99.19 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.745 0.307 . . . . 0.0 110.373 -179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -88.14 143.65 26.93 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.745 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 73.1 m80 53.76 90.69 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.602 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -74.95 128.29 35.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.103 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -107.94 124.91 50.85 Favored 'General case' 0 N--CA 1.464 0.275 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.44 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.78 -12.63 59.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.53 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -63.22 -39.28 97.71 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.949 -0.86 . . . . 0.0 110.949 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -112.79 134.42 54.32 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.86 0.362 . . . . 0.0 110.48 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -101.89 116.01 31.79 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.297 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.502 ' N ' ' CD ' ' A' ' 409' ' ' GLN . 3.2 pm0 -130.44 146.73 52.04 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 90.3 t80 . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.554 -179.9 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 8.7 m . . . . . 0 N--CA 1.492 1.632 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -157.59 151.76 24.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.512 -179.909 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 372' ' ' ASP . 67.0 t0 -147.25 131.64 17.59 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.617 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.432 ' N ' ' OD1' ' A' ' 371' ' ' ASP . 55.5 t0 56.67 34.78 25.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.635 179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' A' ' 376' ' ' LEU . 68.2 t0 -83.68 115.73 22.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.387 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . 0.413 ' OD1' ' O ' ' A' ' 374' ' ' ASN . 57.2 t-20 -64.79 -39.66 93.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.547 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 62.4 t80 -59.56 -46.64 88.32 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.558 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.431 ' O ' ' O ' ' A' ' 373' ' ' ASP . 8.9 mt -95.46 133.13 39.79 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.642 179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 32.7 t 54.94 75.08 0.64 Allowed Pre-proline 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.323 179.795 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -59.49 144.97 99.27 Favored 'Trans proline' 0 C--N 1.304 -1.806 0 C-N-CA 122.899 2.399 . . . . 0.0 112.02 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.486 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.7 mt -64.0 -42.99 97.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.469 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -42.97 -20.04 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.598 -179.707 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.486 ' N ' ' O ' ' A' ' 379' ' ' ILE . 53.5 t -65.66 -43.14 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.535 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . . . . . . . . . . . -62.44 -38.7 96.75 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -61.84 -40.65 96.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.848 0.356 . . . . 0.0 110.311 179.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -64.15 -37.18 86.53 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.421 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . 0.667 HD23 ' O ' ' A' ' 385' ' ' LEU . 2.1 tt -61.9 -44.13 97.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.151 0.501 . . . . 0.0 110.319 -179.339 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -62.42 -37.9 87.6 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.425 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -62.84 -40.69 99.55 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.3 -42.67 96.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.973 0.416 . . . . 0.0 110.494 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -59.78 -36.88 77.61 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.521 -179.71 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 4.8 mm -63.73 -42.7 96.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.485 179.715 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 8.9 mt -61.41 -40.69 95.32 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.422 -179.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . . . . . . . . . 98.4 t -64.79 -41.0 90.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.547 -179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.7 mt -61.15 -41.46 96.8 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.773 -179.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 4.9 tt -61.82 -43.27 99.18 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.7 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.08 -36.11 82.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.417 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -59.46 -45.08 92.64 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.631 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 37.7 m-85 -62.42 -45.59 92.44 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.741 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 96.6 mt -64.14 -42.44 95.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.437 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -62.96 -33.63 87.72 Favored Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.424 ' O ' ' O ' ' A' ' 401' ' ' LYS . 55.8 tp -63.13 -41.3 99.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.792 0.329 . . . . 0.0 110.643 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . 0.424 ' O ' ' O ' ' A' ' 400' ' ' LEU . 88.7 tttt 51.67 103.73 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.556 -179.451 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -73.13 138.77 45.97 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.666 179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -99.9 127.55 46.07 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.31 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -104.17 133.44 49.08 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.479 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -76.91 -36.48 56.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.533 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.22 -40.62 98.14 Favored Glycine 0 CA--C 1.52 0.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.402 ' HB3' HE21 ' A' ' 409' ' ' GLN . 90.1 m-85 -114.29 137.81 51.32 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.981 0.42 . . . . 0.0 110.555 -179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . 0.528 ' O ' ' NE2' ' A' ' 409' ' ' GLN . 80.0 tt0 -85.08 115.7 23.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.351 -179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' A' ' 408' ' ' GLU . 75.1 mm-40 -130.9 146.68 52.39 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.953 0.406 . . . . 0.0 110.499 179.642 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . 0.402 ' OXT' ' NZ ' ' A' ' 401' ' ' LYS . 93.5 t80 . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.576 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 369' ' ' SER . . . . . . . . . . . . . 24.9 m . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -65.35 -37.29 86.6 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.65 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 371' ' ' ASP . . . . . . . . . . . . . 34.3 p30 -88.81 -1.41 58.07 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.595 -179.765 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 372' ' ' ASP . . . . . 0.427 ' O ' ' OD1' ' A' ' 372' ' ' ASP . 68.1 t0 -64.24 -36.32 83.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.497 179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.01 143.78 49.04 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.522 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 374' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 55.8 34.05 22.69 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 375' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -61.12 -42.24 98.18 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.462 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 376' ' ' LEU . . . . . 0.607 ' N ' HD12 ' A' ' 376' ' ' LEU . 9.5 mp -66.67 138.21 57.26 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.499 -179.593 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 377' ' ' VAL . . . . . . . . . . . . . 5.9 t 54.17 60.0 11.31 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.39 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 378' ' ' PRO . . . . . 0.504 ' O ' HG12 ' A' ' 381' ' ' VAL . 58.9 Cg_endo -73.15 150.24 47.49 Favored 'Trans proline' 0 C--N 1.308 -1.596 0 C-N-CA 122.781 2.321 . . . . 0.0 112.127 -179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 379' ' ' ILE . . . . . 0.488 ' O ' ' N ' ' A' ' 381' ' ' VAL . 96.4 mt -63.95 -42.89 97.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.486 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 380' ' ' ALA . . . . . . . . . . . . . . . -43.07 -20.01 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.503 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 381' ' ' VAL . . . . . 0.57 HG13 ' N ' ' A' ' 382' ' ' GLY . 8.0 p -59.22 -44.09 91.18 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.367 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.322 -179.049 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 382' ' ' GLY . . . . . 0.57 ' N ' HG13 ' A' ' 381' ' ' VAL . . . -65.91 -37.54 93.37 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.881 -0.888 . . . . 0.0 110.881 -179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 383' ' ' ALA . . . . . . . . . . . . . . . -63.49 -39.58 94.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.762 0.315 . . . . 0.0 110.458 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 384' ' ' ALA . . . . . . . . . . . . . . . -61.52 -47.17 86.8 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.529 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 385' ' ' LEU . . . . . . . . . . . . . 5.6 mt -67.21 -39.97 86.37 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.212 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 386' ' ' ALA . . . . . . . . . . . . . . . -64.36 -38.04 89.62 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.561 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -64.73 -42.97 96.93 Favored Glycine 0 CA--C 1.522 0.504 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -179.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 388' ' ' VAL . . . . . 0.411 ' O ' HG23 ' A' ' 392' ' ' VAL . 66.3 t -69.05 -41.76 81.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.033 0.444 . . . . 0.0 110.698 -179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 389' ' ' LEU . . . . . . . . . . . . . 5.8 tt -58.28 -39.73 80.04 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.811 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 390' ' ' ILE . . . . . . . . . . . . . 95.7 mt -69.34 -41.53 80.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.974 178.913 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 391' ' ' LEU . . . . . . . . . . . . . 11.4 mt -61.44 -39.4 90.71 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.261 -178.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 392' ' ' VAL . . . . . 0.411 HG23 ' O ' ' A' ' 388' ' ' VAL . 89.6 t -63.56 -39.56 85.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.045 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 393' ' ' LEU . . . . . . . . . . . . . 5.8 mt -60.15 -40.37 89.62 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.318 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 394' ' ' LEU . . . . . . . . . . . . . 5.1 tt -61.57 -43.11 99.46 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.379 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 395' ' ' ALA . . . . . . . . . . . . . . . -66.2 -38.63 88.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.557 179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 396' ' ' TYR . . . . . . . . . . . . . 80.5 t80 -60.4 -43.21 96.92 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.494 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 397' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -62.12 -44.99 95.43 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.904 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 398' ' ' ILE . . . . . . . . . . . . . 91.7 mt -63.58 -42.47 96.22 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.416 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 399' ' ' GLY . . . . . . . . . . . . . . . -64.98 -39.26 96.33 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 400' ' ' LEU . . . . . 0.581 HD13 ' O ' ' A' ' 400' ' ' LEU . 0.2 OUTLIER -62.5 -42.37 99.45 Favored 'General case' 0 N--CA 1.449 -0.5 0 CA-C-O 121.155 0.502 . . . . 0.0 110.673 -179.622 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 401' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -65.55 138.58 58.15 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.17 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 402' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -57.39 -44.95 84.92 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.612 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 403' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -77.38 135.7 38.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.271 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 404' ' ' HIS . . . . . . . . . . . . . 78.2 m80 -109.54 142.21 40.92 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.906 0.384 . . . . 0.0 110.47 179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 405' ' ' ALA . . . . . . . . . . . . . . . -77.88 -12.32 59.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.595 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 406' ' ' GLY . . . . . . . . . . . . . . . -64.1 -38.75 96.42 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 111.056 -0.817 . . . . 0.0 111.056 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 90.4 t80 -77.84 136.41 38.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.849 0.357 . . . . 0.0 110.579 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 408' ' ' GLU . . . . . . . . . . . . . 70.6 mm-40 -135.3 147.52 49.21 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 121.029 0.442 . . . . 0.0 110.536 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 409' ' ' GLN . . . . . 0.59 ' CD ' ' H ' ' A' ' 409' ' ' GLN . 2.0 pm0 -72.41 137.29 46.4 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.521 179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 410' ' ' PHE . . . . . . . . . . . . . 93.9 t80 . . . . . 0 C--O 1.219 -0.519 0 CA-C-O 118.006 -0.997 . . . . 0.0 110.531 179.381 . . . . . . . . 0 0 . 1 stop_ save_